Clinical Development
LDK378
Clinical Trial Protocol CLDK378A2203 / [STUDY_ID_REMOVED]
A phase II, multicenter, single -arm study of oral LDK378 in 
crizotinib naïv e adult patients w ith ALK-activated non -small 
cell lung cancer
Authors  
Document type Amended Protocol Version 
EUDRACT number 2012 -003474 -36
Version number 04
(Clean )
Development phase II
Document status Final
Release date 11-Dec- 2015
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 6
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol summary .............................................................................................................. 11
Amendment 4 .................................................................................................................... 14
Amendment 3 .................................................................................................................... 15
Amendment 2 .................................................................................................................... 18
Amendment 1 .................................................................................................................... 20
1Background ........................................................................................................................ 24
1.1 Overview of disease pathogenesis, epidemiology
 and current treatment .............. 24
1.1.1 Locally  advanced or metastatic no n-small cell lung cancer 
(NSCL C)............................................................................................... 24
1.1.2 Targeted therapies in NSCL C
............................................................... 24
1.1.3 ALK positive NSCL C
........................................................................... 25
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 26
1.2.1 Overview of LDK378 ........................................................................... 26
1.3 Risks and benefits .................................................................................................. 33
2Rationale ................................ ................................ ................................ ............................ 36
2.1 Study  rationale and purpose ................................................................................... 36
2.2 Rationale for the stud y design ............................................................................... 37
2.3 Rationale for dose and regimen selection .............................................................. 38
3Objectives and endpoints ................................ ................................ ................................ ...38
4Study  design ...................................................................................................................... 41
4.1 Description of stud y design ................................................................................... 41
4.2 Tumor sample requirements .................................................................................. 42
4.2.1 Archival tissue ....................................................................................... 43
4.2.2 New biopsies ......................................................................................... 43
4.2.3 Tumor samples anal yses....................................................................... 43
4.3 Definition of end of the study ................................................................................ 44
4.4 Early study termination .......................................................................................... 45
5Population ................................ ................................ ................................ .......................... 45
5.1 Patient population .................................................................................................. 45
5.2 Inclusion criteria .................................................................................................... 46

Novartis Confidential Page 3
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
5.3 Exclusion criteria ................................ ................................ ................................ ...47
6Treatment ........................................................................................................................... 50
6.1 Study  treatment ...................................................................................................... 50
6.1.1 Dosing regimen ..................................................................................... 50
6.1.2 Guidelines for continuation of treatment .............................................. 51
6.1.3 Treatment duration ................................................................................ 51
6.1.4 Definition of treatment cycle ................................................................ 52
6.2 Dose modifications ................................................................................................ 52
6.2.1 Dose modification and dose delay ........................................................ 52
6.2.2 Treatment interruption and treatment dis continuation
.......................... 52
6.2.3 Criteria for LDK378 dose modifications .............................................. 53
6.2.4 Follow -up for toxicities ......................................................................... 59
6.3
Concomitant medications ...................................................................................... 63
6.3.1 Permitted concomitant therap y
............................................................. 64
6.3.2 Prohibited concomitant therap y
............................................................ 65
6.4 Patient numbering, treatment assignment or randomization ................................. 67
6.4.1
Patient numbering ................................................................................. 67
6.4.2
Treatment assignment or randomization............................................... 67
6.4.3 Treatment blinding ................................................................................ 67
6.5 Study  drug preparation and dispensation ............................................................... 67
68
68
6.5.3 Study  drug compliance and accountabilit
y ........................................... 68
6.5.4 Disposal and destruction ....................................................................... 69
7
Visit schedule and assessments ......................................................................................... 69
7.1 Study  flow and visit schedule ................................................................................ 69
7.1.1 Pre-screening ......................................................................................... 75
7.1.2 Screening ............................................................................................... 75
7.1.3 Treatment period ................................................................................... 76
7.1.4 Discontinuation of study  treatment ....................................................... 77
7.1.5 Follow -up period ................................................................................... 78
7.1.6 Lost to follow -
up................................................................................... 78
7.2 Assessment ty pes................................................................................................... 79
7.2.1 Efficacy  assessments ............................................................................. 79
7.2.2 Safety  and tolerability  assessments ....................................................... 82
86

Novartis Confidential Page 4
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
88
7.2.5 Resource utilization ............................................................................... 89
89
8Safety  monitoring and reporting ........................................................................................ 90
8.1 Adverse events (AEs) ............................................................................................ 90
8.1.1
Definitions and reporting ...................................................................... 90
8.1.2 Laboratory  test abnormalities ................................................................ 91
8.1.3
Adverse events of special interest......................................................... 92
8.2 Serious adverse eve nts........................................................................................... 92
8.2.1
Definitions............................................................................................. 92
8.2.2
Reporting............................................................................................... 92
8.3 Emergency  unblinding of treatment assignment ................................................... 93
8.4 Pregnancies ............................................................................................................ 93
8.5 Warnings and precautions ...................................................................................... 93
8.6 Data Monitoring Committee (DMC) ..................................................................... 94
8.7 Steering Committee (SC) ....................................................................................... 94
9Data collection and management ....................................................................................... 94
94
9.2 Site monitoring ...................................................................................................... 95
95
96
10Statistical methods and data anal ysis................................................................................ 97
10.1 Analy sis sets .......................................................................................................... 97
10.1.1 Full Anal ysis Set ................................................................................... 97
10.1.2 Safety  Set
.............................................................................................. 97
10.1.3
Per-Protocol Set .................................................................................... 97
98
10.2 Patient demographics/other baseline characteristics ............................................. 98
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ....................... 98
10.4 Primary  objective ................................................................................................... 98
10.4.1 Variable ................................................................................................. 98
10.4.2 Statistical hy pothesis, model, and method of analysis .......................... 98
10.4.3 Handling of missing values/censoring/discontinuations ....................... 99
10.4.4 Supportive analy ses............................................................................... 99
10.5 Secondary  objectives ............................................................................................. 99
10.5.1 Key secondary  objective(s) ................................................................... 99

Novartis Confidential Page 5
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
10.5.2 Other secondary  efficacy objectives ................................ ................... 100
10.5.3 Safety  objectives ................................ ................................ ................. 100
102
102
103
104
10.7 Interim anal ysis.................................................................................................... 104
10.8
Sample size calculation........................................................................................ 105
10.9 Power for anal ysis of key secondary  variables
.................................................... 105
11Ethical considerations and administrative procedures .................................................... 105
11.1 Regulatory
 and ethical compliance ...................................................................... 105
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 105
106
11.4 Discontinuation of the st udy................................................................................ 106
11.5 Publication of study  protocol and results ............................................................. 106
107
107
11.8
Audits and inspections......................................................................................... 108
11.9 Financial disclosures ............................................................................................ 108
12Protocol adherence .......................................................................................................... 108
12.1 Amendments to the protocol ................................................................................ 108
13References (available upon request) ................................................................................ 109
14Appendices ...................................................................................................................... 111
 
112
114

Novartis Confidential Page 6
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
List of figures
Figure 1 -1 Waterfall plot of reduction in sum of longest tumor diameters ............ 31
Figure 4 -1 Study  design .......................................................................................... 44
List of tables
Table 1
-1 All grades (at least 10%) and grade 3 -4 adverse events, regardless 
of study  drug relationship, by  preferred term in patients treated in 
the 750 mg dose group (Data cut -off date: )..................... 29
Table 1-2 Study  CLDK378 X2101 Response Rate ................................................ 31
Table 3
-1 Objectives and related endpoints .......................................................... 39
Table 6
-1 Dose and treatment schedule................................................................. 50
Table 6
-2 Dose reduction steps for LDK378 ......................................................... 53
Table 6
-3 Criteria for interruption and re- initiation of LDK378 treatment ........... 54
Table 6-4 Follow -up eval uations for selected toxicities........................................ 59
.67
.68
Table 7
-1 Visit evaluation schedule ...................................................................... 70
Table 7
-2 WHO performance status scale ............................................................. 83
Table 7
-3 Clinical laboratory  parameters collection plan ..................................... 84
86
87
Table 10
-1 Operating characteristics of Simon’s optimal two- stage design ......... 105
 
 
112
112
113
113

Novartis Confidential Page 7
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
List of abbreviations
AE Adverse event
ALCL Anaplastic large cell lymphoma
ALK Anaplastic lymphoma kinase
ALT Alanine aminot ransferase
AST Aspartate aminotransferase
AUC Area under the plasma (serum, or blood) concentration versus time curve
AUC0 -24h Area under the plasma (serum, or blood) concentration versus time curve from time zero to 24 
hours
AUCinf Area under the plasma (serum, or blood) concentration versus time curve from time zero to 
infinity
AUCtau Area under the plasma (serum, or blood) concentration versus time curve from time zero to end 
of dosing period
AUClast Area under the concentration -time curve from time zero to the last measurable concentration 
time
BIRC Blinded Independent Review Committee
BLRM Bayesian logistic regression model
CI Confidence interval
CL Clearance
DBP Diastolic blood pressure
Cmax Maximum (peak) concentration of drug in plasma
Cmin Minimum (trough) concentration of drug in plasma
CMV Cytomegalovirus
CNS Central nervous system
CR Complete response
CRO Contract Research Organization
CSR Clinical study report
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome P450
DCR Disease control rate
D Entered into database
DILI Drug Induced Liver Injury
DLT Dose limiting toxicity
DMC Data Monitoring Committee
DOR Duration of response
EBV Epstein -Barr Virus
EC Ethics Committee
ECG Electrocardiogram
eCRF Electronic Case Report Form
EGFR Epidermal growth factor receptor
EML4-ALK Echinoderm microtubule associated protein like 4 -anaplastic lymphoma kinase
EOT End of treatment
FAS Full analysis set
FDA Food and Drug Administration
FISH Fluorescent in situ hybridization
FSH Follicle -stimulating hormone
GCP Good Clinical Practice

Novartis Confidential Page 8
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
GGT Gamma -glutamyl transpeptidase 
HA Health Authorities
HED Human equivalent dose
Hgb Hemoglobin
HSV Herpes Simplex Virus
IB Investigator’s brochure
IC50 Half maximal (50%) inhibitory concentration
ICF Informed consent form
ICH International Conference on Harmonization
IUD Intrauterine device
IUS Intrauterine system
IV Intravenous(ly)
IEC Independent Ethics Committee
ILD Interstitial Lung Disease
IRB Institutional Review Board
LFT Liver function test
LH Luteinizing hormone
LLN Lower limit of normal
MRI Magnetic resonance imaging
MTD Maximum tolerated dose
N/A Not applicable
NCCN National Comprehensive Cancer Center
NSCLC Non-small cell lung cancer
OIRR Overall intracranial response rate
ORR Overall response rate
PD Progressive disease
PFS Progression -free survival
PI Principal investigator
PK Pharmacokinetics
PPS Per-protocol set
PR Partial response
QTc Corrected QT interval
QTcF Corrected QT interval using Fridericia formula
QD quaque diem /once daily
Rvalue ALT/ALP in x ULN
Racc Accumulation ratio
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analysis
RECIST Response Evaluation Criteria In Solid Tumors
SAE Serious adverse event
SBP Systolic Blood Pressure
SC Steering Committee
SD Stable disease
SEC Safety event categories
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic pyruvic transaminase

Novartis Confidential Page 9
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
SHBG Sex hormone binding globulin
SI units Standard international units
SUSARs Suspected unexpected serious adverse reactions
t1/2 Elimination half -life associated with the terminal slope (lambda_z) of a semi logarithmic 
concentration -time curve (time).
TBIL Total Bilirubin
TKIs Tyrosine kinase inhibitors
Tmax The time to reach maximum plasma concentration
TTR Time to response
ULN Upper limit of normal
Vss Plasma volume of distribution
VATS Video -assisted thoracic surgery
VEGF -A Vascular endothelial growth factor -A
WHO World Health Organization

Novartis Confidential Page 10
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biological samples A biological specimen including , for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study subject or study patient
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. 
treatment group) at the same time
Cycles Number and timi ng or recommended repetitions of therapy are usually expressed as 
number of days (eg, q 21 days)
Enrollment Point/time of patient entry into the study; the point at which informed consent must 
be obtained (ie, before starting any of the study procedures d escribed in the 
protocol)
Investigational drug The drug whose properties are being tested in the study; this definition is consistent 
with US CFR 21 Section 312.3 and is synonymous with “investigational new drug”
Subject number A unique identifier number (consisting of the center number and a patient -specific 
number) assigned to each patient who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Premature patient 
withdrawalPoint/time when the patient exits from the study before the planned completion of all 
study drug administration and assessments; all study drug administration is 
discontinued and no further assessments are planned, unles s the patient is to be 
followed for progression and/or survival
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, completion of treatment, etc.
Stage in cancer The e xtent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has spread 
from the original site to other parts of the body
Stop study participation Point/time at which the pati ent came in for a final evaluation visit or when study drug 
was discontinued whichever is later
Study drug Any drug administered to the patient as part of the required study procedures; 
includes investigational drug and any combination or control drug(s)
Study drug discontinuation Point/time when patient permanently stops taking study drug for any reason; 
Variable A quantity subject to variation of values used in the data analysis; derived directly or 
indirectly from data collected using specified assessments at specified time points
Withdrawal of consent Withdrawal of consent occurs only when a patient does not want to participate in the 
study anylonger, and does not want any further visits or assessments, and does 
not want any further study related contact

Novartis Confidential Page 11
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Protocol summary
Protocol number CLDK378A2203
Title A phase II, multicenter, single -arm study of oral LDK378 in crizotinib naïve adult 
patients with ALK- activated non -small cell lung cancer
Brief title LDK378 in non -small cell lung cancer patients with ALK rearrangements who are 
crizotinib naïve
Sponsor and Clinical 
PhaseNovartis, Phase II
Investigation ty pe Drug
Study  type Interventional
Purpose and rationale ALK+ NSCLC patients have only crizotinib as an effective ALK targeted treatm ent 
option and therefore novel ALK targeted therapies with activity against ALK+ NSCLC 
are needed.
The available data indicate that LDK378 has substantial antitumor activity in patients 
with ALK rearranged NSCLC
Primary  Objective and 
Key Secondary  
Objecti ve(s)Primary objective: To demonstrate the antitumor activity of LDK378, as measured by 
overall response rate (ORR) to LDK378 by investigator assessment
Key secondary objectives: To evaluate response related endpoints as assessed by 
investigator and blinded independent review committee (BIRC): duration of response 
(DOR), disease control rate (DCR), time to response (TTR), overall intracranial 
response rate (OIRR); and to assess ORR by BIRC assessment
Secondary  Objectives Objective 1: To evaluate the safety profile of LDK378
Objective 2: To evaluate progression -free survival (PFS)
Objective 3: To evaluate overall survival (OS)
Study  design This is a single -arm, open- label, two -stage multicenter, phase II study. Patients will be 
pre-screened for ALK positive status. Treatment with LDK378 at 750 mg qd will 
continue until the patient experiences unacceptable toxicity that precludes further 
treatment, discontinues treatment at the discretion of the investigator or patient, starts 
a new anti -cancer therapy and/or dies. LDK378 may be continued beyond RECIST-
defined PD as assessed by the investigator, if in the judgment of the investigator, 
there is evidence of clinical benefit. In these patients tumor assessment should 
continue as per the schedule of assessme nts until treatment with LDK378 is 
permanently discontinued. Patients who discontinue the study medication in the 
absence of progression will continue to be followed for tumor assessment until the 
time of PD as assessed by the investigator.
The study will use a Simon’s optimal two -stage design. Stage 1 will consist of 43 
patients and their data up to 6 cycles of treatment unless a patient has discontinued 
treatment earlier or a confirmed response to treatment has been observed prior to 
completing 6 cycles . The trial will be stopped at Stage 1 if 16 or fewer responses are 
observed. If at the time that the last patient is enrolled to Stage 1 a minimum of 17 
responses have not yet been observed, accrual may be temporarily suspended during 
the analysis of Stage 1. Stage 2 will include an additional 62 patients. The primary 
analysis will occur when all 105 patients have completed 6 cycles of treatment or 
discontinued treatment earlier.
Population Male and female patients aged 18 or over with ALK -rearranged NSCLC. Patients 
must have received no prior crizotinib, and must be chemotherapy -naïve or have 
been treated with cytotoxic chemotherapy (up to 3 prior lines).

Novartis Confidential Page 12
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Inclusion criteria Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that 
carries an ALK rearrangement, as per the FDA -approved Vysis ALK break -apart 
FISH assay (Abbott Molecular Inc.).
Age 18 years or older at the time of informed consent.
Patients must have stage IIIB or IV NSCLC.
Patients may have received up to 3 lines of cy totoxic chemotherapy to treat their 
stage IIIB or IV NSCLC
Patients who have been treated with chemotherapy must have progressed during 
or after the last chemotherapy regimen received prior to the first dose of LDK378
Patients must have a tumor tissue sample available, preferably being a new biopsy 
but otherwise being an archival sample collected either at the time of diagnosis of 
NSCLC or any time since, for assessing ALK rearrangements using the FDA -
approved Vysis ALK break -apart FISH assay.
Patients must have recovered from all toxicities related to prior anticancer 
therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or 
grade 2 diarrhea despite optimal supportive therapy who will not be allowed to 
participate in the study.
Exclusion criteria Prior treatment with crizotinib, or any other ALK inhibitor investigational agent, for 
NSCLC
Patients with known hypersensitivity to any of the excipients of LDK378.
Patients with symptomatic central nervous system (CNS) metastases who are
neurologically unstable or have required increasing doses of steroids within the 2 
weeks prior to study entry to manage CNS symptoms.
History of carcinomatous meningitis.
Presence or history of a malignant disease other than NSCLC that has been 
diagnosed and/or required therapy within the past 3 years.
Clinically significant, uncontrolled heart disease.
Investigational and 
reference therapyLDK378
Efficacy  assessments Tumor assessment by RECIST 1.1 as evaluated by investigator and by a BIRC
Safety  assessments Hematology, biochemistry, urinalysis, coagulation, pregnancy test and hormones 
(males only)
ECG
Performance status
Vital signs
Adverse events
Other assessments Trough and sparse PK

Novartis Confidential Page 13
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Data analysis The cut -off date for the primary analysis of this trial will be the time when all 105 
patients have completed 6 cycles of treatment or have discontinued treatment. The 
ORR per RECIST 1.1 by investigator assessment and by BIRC assessment will be 
estimated and the 90% confidence interval (CI) provided. If the true ORR is 50% 
(under the alternative hypothesis), approximately 105 patients are required to reject 
the null hypothesis of ORR ≤ 35% with a one -sided alpha of 0.05 b ased on Simon’s 
optimal two -stage design. If45 or more responses are seen in 105 total patients 
(estimated ORR of 42.9%), then the null hypothesis will be rejected and the trial 
declared positive. If the study is terminated early at the end of Stage 1, th en the study 
will be considered to have failed to reject the null hypothesis. The uniformly minimum 
variance unbiased estimator (UMVUE) and the 90% CI from 
Atkinson andBrown (1985) will also be present ed.
DOR will be listed by patient and may be described using Kaplan -Meier methods and 
relevant statistics if appropriate. DCR and OIRR will be estimated and the 90% CI 
provided. TTR, PFS, and OS will be described using Kaplan -Meier methods and 
appropriate summary statistics.
Adverse events and laboratory abnormalities will be summarized and listed.
Key words ALK, NSCLC, LDK378

Novartis Confidential Page 14
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Amendment 4
Amendment rationale
As of the release date of this amendment the recruitment has been completed and 132 patients 
have been screened to the study . A total of 124 patients have been treated.
This amendment has been implemented to:
Update the protocol to include follow up evaluations for hepatic toxicities and work -up 
guidelines for potential Drug Induced Liver Injury  (DILI) cases in order to optimize the 
patient safet y.
Update the dose guidance modification for QTcF text to provide clarification on 
monitoring procedure.
Update the guidance related to corticosteroids use
Update of the definition of the End of Study
Editorial changes and text corrections were made for clarification, where required.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underl ined font for insertions.
The following 
sections were changed:
List of abbreviations updated with commonly  used abbreviations such as R value, TBIL , 
DILI , EBV, CMV, and HSV
Section 4.3: the definition of the End of Study  has been updated to allow patients’ 
transition to othe clinical studies or to patient support programs 
Section 6.2.4.2: updated guidelines to monitor l iver abnormalities for p atients with 
transaminase increase combined with total bilirubin (TBIL) increase which may be 
indicative of potential DILI
Table 6-3: updated dose modifica tion guidelines to monitor Grade 3 QTc prolongation 
Section 6.3.1.1: updating corticosteroide use guidance and wording on increasing doses of 
corticosteroids use ha sbeen removed.
Section 8.2.2: Updated reporting instructions. 
Editorial and ty pographical changes throughout the document as required
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 

Novartis Confidential Page 15
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Amendment 3
Amendment rationale
As of the release date of this amendment the recruitment has been completed and 132 patients 
have been screened to the study . A total of 124 patients have been treated.
This amendment has been implemented to include availability  of new safety  data as presented 
in the Investigator’s Brochure and to clarify  sections of the protocol where additional 
guidance was required:
Update of safet y data in the protocol to match the Investigator’s Brochure Edition 7 
(released on 12 Jun 2014). The associated Informed Consent Form (ICF) has been updated 
separately  to this protocol
Update of the LDK378 dose modific ation and follow up of toxicities in case of elevations 
of pancreatic enzy mes (lipase and/or amy lase) have been made based on currentl y 
available safet y data. Pancreatic enzyme elevations (lipase and/or am ylase) occur in 
patients treated with LDK378. Clini cal data suggest that a small proportion (<1%) of 
patients treated with LDK378 can develop clinical pancreatitis, and the causal role of 
LDK378 in these cases cannot be excluded. Due to this finding, the protocol has been 
amended to include additional dose modification and follow up monitoring language for 
patients who may  experience this safety  finding 
An evaluation of the anticipated benefits and risks has been added to the protocol to 
comply  with EU clinical trial regulations. 
Revision of s ections 7.1.4, 7.1.5 and 7.1.6 related to study  discontinuation to bring 
clarification and additional guidance regarding study treatment discontinuation and 
withdrawal of consent 
In addition, editorial changes and text corrections were made for clarification, where r equired.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined font for insertions.
The following sections were changed:
List of abbreviations updated with commonly  used abbreviations such as GGT, ILD and 
NCCN
Glossary  of terms updated with definitions for biological samples, study  drug 
discontinuation and withdrawal of consent
Section 1.2.1.2.1: clinical safet y and tolerabili ty data updated to reflect data most recentl y 
available from ongoing study  CLDK378X2101
Section 1.2.1.1.3, Section 6.3.1.2: Updated nonclinical PK and metabolism data from 
recent studies. Evaluation of DDI potential was re -conducted for NDA submission. Usi ng 
the 2012 FDA Draft Guidance “Drug Interaction Studies – Study  Design, Data Anal ysis, 
Implications for Dosing, and Labeling Recommendations” and the 2012 EMA “Guideline 
on the I nvestigation of Drug Interactions,” the mechanistic static model determined t hat 

Novartis Confidential Page 16
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
the inhibitory  potential of LDK378 is low for CYP2C8 and CYP2B6 (AUCR <1.25). As 
such, the sentence regarding LDK378 being a potent reversible inhibitor of CYP2C8 and 
CYP2B6 was removed
Section 1.2.1.2.4: updated to reflect the most recently  available food effect study  data  
Section 1.3: added new section “Risks and benefits”
Section 6.2.1: sub- title has been updated to specify  that guidelines are related to toxicities 
other than those listed in Table 6 -3
Section 6.2.2: section updated with instructions that guidelines for follow -up of study  drug 
related AEs or abnormal laboratory  values must be followed as described in Section 6.2.4
Section 6. 2.3: clarification that dose reductions will be in 150 mg decrements per 
reduction and that once the dose of LDK378 has been reduced due to toxicity , it should 
not be re -escalated
Table 6-3: updated to reflect themost recently  available data where criteria for 
interruption and re -initiation of L DK378 treatment are now less stringent (such as 
allowing maintenance of dose level in the case of neutropenia Grade 3 and elevated 
ALT/AST Grade 2), while for other criteria, more stringent dose modifications have been 
introduced (such as for elevated ALT/AST Grade 2 and concurrent total bilirubin >2.0 
xULN, pneumonitis al l grades and QTC prolongation Grade 3). Criteria for interruption 
and re -initiation of LDK378 treatment for brady cardia ,hypergly cemia and p ancreatitis has 
been added to Table 6-3
Section 6.2.4.2 and Table 6- 4: updated guidelines to monitor liver abnormalities for 
patients with baseline liver metastases and  elevated ALT/AST Grade 2 
Section 6.2.4.3: addition of guidelines for the follow -up of laboratory  pancreatic 
abnormalities Table 6-4: addition of follow- up evaluations for pancreatic toxicities
Section 6.2.4.6: updated safet y data for h ypophosphatemia
Section 6.2.4.8: addition of guidelines for anticipated risks and safety  concerns for the 
study  treatment
Section 6.3.1.1: clarific ation added when increasing doses of corticosteroids are used
Section 6.3.1.2: updated CYP450 drug interactions with L DK378
Section 6.3.1.4: updated with LDK378 dosing guidance in association to radiotherap y and 
surgical resection in order to align with program level language
Section 6.3.2.1: addition of targeted therap y to other anticancer therapies 
Section 6.3.2.6: clarification that concomitant use of medications that are CYP2C9 and 
CYP3A4/5 substrates with narrow therapeutic index is not permitted wi th LDK378
Section 6.3.2.8: updated with most recent data on QTc prolongation from ongoing study  
CLDK378X2101   
Section 7.1.4: The title of the section is changed to reflect updated guidance on how to 
follow subjects who discontinue study  treatment, either some or all of the visits, withdra w 
consent or are lost to follow
-up
Section 7.1.4.2: added new section ‘Withdrawal of consent ‘
Section 7.1.6: added new section ‘Lost to follow –up‘ 

Novartis Confidential Page 17
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Section 4.1 and 7.2.1.2: deletion of the start of new anti- cancer therap y as an allowable 
reason to stop collecting tumor assessments to enable sensitivity  anal ysis of PFS following 
a pure intent -to-treat principle where start of new antineoplastic therapy  does not result in 
censoring for PFS
Table 7
-3:clinical laboratory  parameters collection plan upated with lipase
Section 8.1.3: updated with the list of adverse events of special interest
Section 13: update to the list of references
Appendix 14.1: table title for prohibited concomitant medications requiring caution has 
been updated with a notation for LDK378, deletion of CYP2C8 substrates and paclitaxel, 
and updated footnotes for clarification
Appendix Table 14
-2: list of medications to be used with caution updated with deletion of 
CYP2B6 and CYP2C8 substrates, clarithrom ycin and telithromy cin
Editorial and ty pographical changes throughout the document as required
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. The changes herein affect the Informed Consent. Sites are required to update 
and submit for approval a revised Informed Consent that takes into account the changes
described in this protocol amendment.
Updates to the safety  data in the associated Informed Consent Form (ICF) to match the 
Investigator’s Brochure Edition 7 (released on 12 Jun 2014) have been performed separatel y 
to this protocol on 15 Sep 2014. 

Novartis Confidential Page 18
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Summar y of previous amendments
Amendment 2
Amendment rationale
As of the release date of this amendment, 57 patients have been screened to the study . 45 
patients have been treated.
This amendment has been implemented to address the availability  of new safet y data as 
represented in the latest Investigator Brochure, to amend the eligible study  population, and to 
clarify  sections of the protocol where additional guidance was required:
Addition a secondary  endpoint of overall intracranial response rate (OI RR) due to the 
interest in L DK378 activity  in the brain
Allowing pre -screening during prior chemotherapy treatment and prior to progression of 
disease
Allowing the enrolment of chemotherap y-naive patients to target the ALK -inhibitors-
naive population regardless of pr evious chemotherapy
Update of safet y data in the protocol and associated I nformed Consent Form (I CF) to 
match the Investigator Brochure Edition 4 (release on 28 June 2013).
Change in definition of duration of response (DOR) in response to health authority  
feedback and based on the advanced cancer under study  and it being difficult to ascertain 
whether a death is due to the underl ying cancer
In addition, editorial changes and text corrections were made for clarification, where required.
This amendment will result in a change to the study  population. There is no anticipated 
extension in the duration or release of results of the study .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol usi ng strike through red font for deletions and red underlined for insertions.
The following sections were changed:
Sections 1.2.1.2.1, 1.2.1.2.2 and 2.1: clinical safety and efficacy  data updated to reflect 
data most recently  available from ongoing studies
Section 1.2.1.2.4: updated with most recent data from clinical pharmacology studies
Sections 1, 5 and 6: I nformation available on pneumonitis cases reported during LDK378 
treatment to date have been summarized, an exclusion criteria for patients with 
pneum onitis added, and dose modification criteria added for patients who experience 
pneumonitis during the course of the stud y.
Sections 2.2, 4.1 and 5: study  population changed to allow patients who are chemotherap y 
naïve to enter the trial.
Section 3: Changed the definition of duration of response (DOR) from ‘time from first 
documented response (PR or CR) to the date of first documented disease progression or 

Novartis Confidential Page 19
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
death due to underl ying cancer’ to ‘time from first documented response (PR or CR) to the 
date of firs t documented disease progression or death due to any  cause’.
Sections 3 and 10: Secondary  endpoint of overall intracranial response rate (OIRR) added
 
 
 
 
Section 5.2: inclusion criteria for potassium, magnesium, phosphorus and total calcium 
changed from requirement to be ≥ LLN to within normal range.
Section 5.3: exclusion criteria updated to specifically  disallow patients with uncontrolled 
diabetes mellitus from entry  to the trial.
Section 6.1.1: guidance on dosing with LDK378 in relation to food intake has been 
updated to reflect latest data on clinical pharmacology .
 
Section 6.2.3: added guidance that once the dose of LDK378 has been reduced due to 
toxicity , it should not be re -escalated.
Section 7.2.1.1: clarification that all imaging assessments pe rformed in the 6 weeks 
leading up to first dose may  be counted as baseline assessments.
Editorial and ty pographical changes through the document as required.
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Inde pendent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.

Novartis Confidential Page 20
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Amendment 1
Amendment rationale
As of the release date of this amendment, 5 patients have been screened to the study . 3 
patients have been trea ted.
This amendment has been implemented to address six main items with the original protocol 
released for the study , reflecting the availability of new toxicity  data, addressing requests 
from health authorities, and clarify ing sections of the protocol where additional guidance was 
required :
To add an ECG assessment for all patients 6 hours after first dose
To provide general guidance on dose modification
To provide guidance on dose modification in response to QTc prolongation
To provide guidance for treatment of hy pophosphatemia
To clarify  tumor sample collection requirements
In addition, editorial changes and text corrections were made for clarification, where required.
This amendment will result in no change to the study  population. There is no anticipated 
extension in the duration or release of results of the study .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following sections of the protocol were changed:
In Section 1.1.3, information on ALK positive NSCL C data and regulatory  approvals status 
have been updated.
 
In Section 1.2.1.1.4, based on emerging safet y data made available, LDK378 may have an 
effect on the QT interval, hence the last sentence regarding “…suggesting that there is no
clinical risk for QTc prolongation” was removed. Additionally  data regarding phototoxicity  
was added. 
In Section 1.2.1.2.1, information on hy pophosphatemia and QT data was added.
 
 
In Section 4.1, naming of the FDA -approved FISH test has been updated and aligned 
throughout the entire document.

Novartis Confidential Page 21
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
In Section 4.2, sub-sections have been added to bring clarity  to thetumor samples 
requirements. In addition, the new biops y sampling timing has been corrected to ‘time of 
progression’ instead of ‘end of treatment’.
In Section 4.3, sentence has been added to confirm Novartis will commit to their reporting 
obligations, for patients receiving LDK378 on a separate protocol.
In Section 5.2, in inclusion criteria no 1, 3 and 4, locally  advanced or metastatic were replaced 
by Stage IIIb or IV, for clarity  purpose. In inclusion criteria no 3, it has been clarified that 
patients must have progressed during or after the last chemotherap y regimen received prior to 
the first dose of LDK378 . In addition, in inclusion no 4, cytotoxic chemotherap y definition 
has been slightly  corrected to include duration of 21 days. In inclusion no 7, abbreviation for 
Alanine transaminase has been corrected to ALT. An additional inclusion criterion was added 
for laboratory  parameters for magnesium, potassium, phosphorus and calcium, and the 
inclusion criteria for creatinine clearance was changed from > 50mL/min to > 30 mL min to 
allow inclusion of patients with moderate renal impairment . Renal clearance of LDK378 is 
less than 1% in rats and monkey s and in preliminary  data from a human ADME study . In 
addition, in the CLDK378X2101 phase I study of over 200 patients, no significant renal 
toxicities were reported, and in the small subgroup of patients with mild renal impairment no 
excess toxicities were noted.
In Section 5.3, exclusion criteria no 5, additional information regarding QTcF calculation has 
been added as it was missing in the original document. In addition, medications with a known 
risk of prolonging the QT interval or inducing Torsades de Pointes has been added as a sub-
bullet in exclusion no 10. Tumor -associated s ymptoms have been clarified in e xclusion no 13.
In Section 6.1.1, meal instructions have been updated to reflect the updated data from food 
effect study .
In Section 6.2.1, general guidelines for dose modifications have been added as per Health 
Authorities request.
In Section 6.2.2, treatment interruption guidance for reasons other than toxicity  has been 
added as it was missing from the original document, and treatment interruption guidance for 
toxicity  has been updated to be aligned with the treatment schedule of 28 day s cycles.
In Table 6-3 and Table 6 -4, ‘total’ was added for bilirubin as it was missing from the original 
document. In addition, guidance on dose modification in response to QTc prolongation was 
added as it was missing from the original document. Table 6-4 was moved to the end of 
section 6.2.4.1, to be consistent with the text.
In Section 6.2.4.2, ‘total’ was added for bilirubin as it was missing from the original 
document.
In Section 6.2.4.6, guidance for the treatment hypophosphatemia was added as it was missing 
in the text .
In Section 6.3.1, clarification has been made when corticosteroids are use when used for CNS 
related s ymptoms.
In Section 6.3.1.5, the use of gastric protection agents has been further clarified.

Novartis Confidential Page 22
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
In Section 6.3.2, a sub -section has been added regarding m edications that may  prolong the QT 
interval or have a known risk of inducing Torsades de Pointes.
In Section 6.4.1, the use of the IRT system has been clarified at the screening visit. 
Information has been as well added in regard to the use of the IRT system when the patient is 
enrolled.
In Section 7.1, Table 7-1 was corrected to reflect the current assessments performed as some 
were not captured in the original document.
In Section 
7.1.3.2, criteria for patient withdrawal have been clarified to reflect Health 
Authorities’ request.
In Section 7.2.1, it has been specified that Contrast -enhanced CT needs to be performed with 
IV contrast, and that upper abdomen needs to be evaluated. In addition, it is now allowed to 
provide as protocol required baseline scans, the scans that were alread y completed during the 
regular work -up of the patient within 6 weeks prior to start of treatment and before signing the 
main study  ICF.
In Section 7.2.2.5, laboratory  evaluations have been re-worded to make the distinction 
between central/local assessments for out-of- schedule assessments and out-of- range 
parameters.
In Section 7.2.2.6, an ECG assessment has been added for all patients 6 hours after first dose. 
Further changes have been done to bring clarit y to the section.
In Section 8.4, clarification has been made that patients who become pregnant during the trial 
will be withdrawn from study  as requested by Health Authorities, and that pregnancy  should 
be followed until 3 months following delivery .
In Section 10, minor changes have been done throughout the section to bring clarit y and to 
align with LDK378 program analysis standards. The definition of the per-protocol set was 
changed to include patients who have a follow -up tumor assessment > 7 weeks (rather than 8 
weeks) after starting treatment to take into consideration the +/-1 week window associated 
with tumor assessments; the definition of safety data set was changed to align with the 
LDK378 program standard (now includes all patients who receive at least one dose of study 
drug).
In Section 14 Appendix I, Table 14-1 references have been updated. Table 14-2 has been 
updated with a list of proton pump inhibitors, as it was missing in the original document. In 
addition a new table showing the list of prohibited QT prolonging drugs has been added as per 
Health Authorities request.
Editorial changes were performed throughout the document.

Novartis Confidential Page 23
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
IRB/IEC
A copy of this amend ed protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herei naffect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.

Novartis Confidential Page 24
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
1.1.1 Locally  advanced or metastatic non- small cell lung cancer (NSCLC)
Lung cancer has been the most common cancer in the world for several decades. In 2008, 
there were an estimated 1.61 million new cases, representing 12.7% of all new cancers 
worldwide. It was also the most common cause of death from cancer, with 1.38 million deaths 
(Ferlay  et al 2010). This year, approximately 160,000 deaths are expected in the US 
(Siegel etal 2012
) and 262,000 in the European Union ( Malvezzi et al 2012 ).
The World Health Organization (WHO) divides lung cancer into 2 major classes based on its 
biology , therap y,and prognosis: non-small cell lung cancer (NSCL C) and small cell lung 
cancer. NSCL C accounts for more than 85% of all lung cancer cases, and it includes 2 major 
types: (1) non-squamous carcinoma (including adenocarcinoma, large -cell carcinoma, other 
cell types); and (2) squamous cell 
(epidermoid) carcinoma. Adenocarcinoma (40% of lung 
cancers) is the most common type of lung cancer seen in the United States and is also the 
most frequently  occurring cell ty pe in nonsmokers ( NCCN Guidelines® v3.2012 ).
Cigarette smoking remains the most important risk factor for lung cancer , although 
approximately  15% of all lung cancers are diagnosed in patients who never smoked.
One reason for the high mortality  rate of l
ung cancer is the advanced stage at diagnosis; only 
25-30% of new NSCL C cases are diagnosed with localized disease that is potentially  curable 
with surgery  (Nguyen et al 2012 ). The majority  of patients are diagnosed with locally 
advanced or metastatic disease and they  are not candidates for surgery .
As summarized in the current NCCN Guidelines for NSCL C, data show that platinum -based 
combination therap y is superior to best supportive care for patients with advanced, incurable 
disease. Platinum -doublets (cisplatin or carboplatin in combination with other chemotherap y 
agents, with or without bevacizumab) is the standard in first line treatment of locall y 
advanced or metastatic NSCL C, unless a patient has a known “druggable” mutation, and is a 
candidate for a targeted therap y (as discussed below). Docetaxel, pemetrexed, erlotinib, or 
platinum doublet (with or without bevacizumab) are recommended as second -line 
chemotherap y regimens for patients who have experienced disease progression during or after 
first-line therap y. The reported response rates to second -line chemotherapy  have generall y 
been less than 10%. Overall, current treatments are not considered satisfactory  for most 
NSCL C pa tients and the prognosis continues to be poor despite chemotherapy  treatment, with 
a 5-year overall survival rate of onl y 15% ( Nguyen et al 2012 ).
1.1.2 Targeted therapies in NSCLC
During 
the last few years, improved knowledge of NSCL C biology  led to the identification of 
molecular events crucial for malignant transformation and cancer cell survival. These aberrant 
molecular events are critical oncogenic drivers and, therefore, represent potential therapeutic 
targets (Gettinger et al 2011). As a result, new targeted treatment options are evolving. 

Novartis Confidential Page 25
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Bevacizumab, a monoclonal antibody  directed against vascular endothelial growth factor -A 
(VEGF -A), and erlotinib and gefitinib, epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs), have been approved for the treatment of NSCL C 
(Gettinger et al 2011). In particular, the case of epidermal grow th factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs) represents a new paradigm in the treatment of NSCL C. 
Mutations in EGFR are found in 10 –26% of NSCLC patients and are associated with response 
to oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and 
erlotinib, and the monoclonal antibody  to EGFR, cetuximab ( National Cancer Institute PDQ®).
Multiple large randomized clinical trials have demonstrated that patients harboring activating 
EGFR mutations benefit more from EGFR TKIs than from standard chemotherapy  in terms of 
response rate, progression free survival, toxicity  profile and quality  of life (reviewed in 
NCCN Guidelines® v3.2012). The success of EGFR TKIs highlights the importance of 
identify ing specific NSCL C molecular drivers to appropriatel y direct targeted agents to 
specific patient populations.
1.1.3 ALK positive NSCLC
The discovery  of anaplastic lymphoma kinase (ALK) rearrangement in NSCL C in 2007 
(Soda et al 2007) represents another important milestone in the era of molecular targeted 
therap y in NSCL C.
ALK was first identified as a chromosome transloca tion-produced protein fusion in the 
majority  of anaplastic large cell lymphomas (ALCL). When fused to other proteins, ALK 
becomes constitutively active, leading to increased catal ytic kinase function, signal -
transduction activity , and oncogenic function. Expression of EML 4-ALK -a new fusion 
protein between ALK and the echinoderm microtubule -associated protein -like 4 (EML4) 
gene -in transgenic mice has been shown to induce tumor formation, suggesting the 
therapeutic potential of targeting the EML 4-ALK fusion protein in NSCLC (Soda et al 2007 ). 
The frequency  of EML 4-ALK rearrangement in patients with NSCLC is relativel y low; it is 
present in approximately 2 -8% of tumors tested (Scagliotti 2012; Takeuchi 2009 ; Soda 2007 ). 
However, considering 
the high incidence of lung cancer, this small percentage translates into 
about 10,000 patients in the United States alone ( Kwak et al 2010 ).
These patients are similar to those with EGFR mutations (i.e., adenocarcinoma, nonsmokers 
or light smokers) except they are often younger. In addition, ALK rearrangements are found 
in patients with adenocarcinoma but are usuall y not been found in squamous cell or large cell 
carcinoma (Shaw et al 2009). ALK rearrangemen ts and other oncogenic drivers such as 
mutant EGFR and oncogenic RAS are generally mutually  exclusive, consistent with the 
notion that ALK rearrangement defines a unique molecular subset of NSCL
C. In these 
patients, ALK rearrangements serve as a key and strong oncogenic driver for NSCL C and 
represent a critical therapeutic target susceptible to targeted ALK kinase inhibition.
Crizotinib, an orally  available small -molecule inhibitor of ALK and MET tyrosine kinases, 
has been rapidl y and successfull y developed in patients with advanced NSCL C who have 
EML 4-ALK rearrangements and have progressed on previous therapy. Crizotinib was 
associated with clinically meaningful response rates of 50% and 61%, respectivel y, in two 
single -arm trials in 255 
patients with local ly advanced or metastatic ALK -positive NSCL C 

Novartis Confidential Page 26
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
(Ou 2011 ). Responses were rapid, with the majority  of patients achieving an objective 
response within the first 8 weeks of treatment, and durable, with a median duration of 
response of 9.78 and 11.22 months, respectivel y, in each of the studies. Based on these data, 
crizotinib (Xalkori®) received accelerated approval by the US Food and Drug Administration 
in August 2011 for the treatme nt of ALK -rearranged NSCL C. It has also been approved in 
South Korea, Switzerland, Japan and Canada and received conditional marketing 
authorization in the EU on 23- Oct- 2012 for the treatment of adult patients with previousl y 
treated ALK-positive advanced NSCL C.Retrospective comparison of these data for the 
subset of patients treated in the second -line to ALK -positive positive patients who were 
treated with other second -line chemotherap y suggested an overall survival advantage (median 
OS: not reached versus 6 months, HR=0.36, p=0.004) ( Shaw et al 2011 ).
While crizotinib has substantial activity  in patients with ALK rearranged NSCL C, these 
cancers invariabl y progress, typically  within 1 year, because of the development of resistance 
to crizotinib ( Ou 2011).
CH5424802 is another ALK inhibitor in clinical development. As opposed to crizotinib, 
CH5424802 is a specific ALK inhibitor. In a phase 1 trial in patients with ALK positive 
NSCL C who have failed prior chemotherap y, but were crizotinib naïve, a response rate of 
85% was reported in 20 patients with measurable lesions (Kiura et al 2012). These data 
highlight the fact that NSCL C harboring ALK rearrangements are responsive to specific ALK 
inhibitors, with a response rate higher to that expected with chemotherap y and at least 
comparable to the response rate obtained after crizotinib. In addition, these data also reaffirm 
that ALK rearrangement represent 
the key oncogenic driver in these tumors and that specific 
ALK inhibition provides substantial anti- tumor activity .
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of LDK 378
LDK378 [5-Chloro -N2-[2-isopropoxy -5-methy l -4- (4-piperidin yl)phen yl]-N4-[2 
(isopropy lsulfony l)phenyl] -2,4- pyrimidinediamine] is an orally  available ALK inhibitor. 
LDK378 is an approximately  20
-fold more potent ALK inhibitor than crizotinib, it is more 
selective for ALK and does not inhibit MET.
In addition, L DK378 shows potent antitumor activity in crizotinib -resistant animal models .
These features support the hy pothesis that LDK378 could be active in NSCLC patients whose 
disease has progressed on crizot inib.
1.2.1.1 Non- clinical experience
1.2.1.1.1 Pharmacology
 
 
 
 

Novartis Confidential Page 27
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
1.2.1.1.2 Antitumor activity in xenograft models
1.2.1.1.3 Non-clinical pharmacokinetics (PKs) and metabolism

Novartis Confidential Page 28
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
1.2.1.1.4 Safety pharmacology and toxicology

Novartis Confidential Page 29
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
1.2.1.2 Clinical experience
1.2.1.2.1 Clinical safety and tolerability
LDK378 is associated with a managea ble safety  profile (Table 1-1). For the 255 patients 
treated at the recommended dose (RD) of 750 mg in the ongoing study [CLDK378X2101] , 
the median duration of exposure as of the  cut-off date was 26.9 weeks (range 0.4 
to 82.3 weeks). The most common AEs regardless of study  drug relationship (incidence ≥25%) 
were diarrhea, nausea, vomiting, alanine aminotransferase (ALT) increa sed, fatigue, 
abdominal pain, decreased appetite, aspartate aminotransferase (AST) increased, and 
constipation. 
The incidence of grade 3
-4 AEs, regardless of study  drug relationship was <10% for all AEs 
except ALT increased (26.7%) (Table 1-1). The incidence of grade 3-4 AEs, regardless of 
study  drug relationship was <5% for all AEs except AST increased (8.2%), diarrhea (5.9%), 
hypergly cemia (5.5%), lipase increased (5.1%), and blood alkaline phosphatas e (ALP) 
increased (5.1%).
Table 1
-1 All grades (at least 10%) and grade 3 -4 adverse events, regardless of 
study  drug relationship, by  preferred term in patients treated in t he 
750 mg dose group (Data cut -off date: )
Preferred termLDK378
750mg
N=255
All Grades Grade 3/4
n (% ) n (% )
Total 255 (100.0) 184 (72.2)
Diarrhea 219 (85.9) 15 (5.9)
Nausea 205 (80.4) 11 (4.3)
Vomiting 153 (60.0) 10 (3.9)
Alanine Aminotransferase 
Increased110 (43.1) 68 (26.7)
Fatigue 102 (40.0) 10 (3.9)
Abdominal Pain 91 (35.7) 3 (1.2)
Decreased Appetite 87 (34.1) 2 (0.8)
Aspartate Aminotransferase 
Increased78(30.6) 21(8.2)
Constipation 73 (28.6) 0
Cough 62 (24.3) 0
Abdominal Pain Upper 58 (22.7) 2 (0.8)
Dyspnea 47 (18.4) 8 (3.1)
Asthenia 45 (17.6) 2 (0.8)
Blood Alkaline Phosphatase 
Increased45 (17.6) 13 (5.1)
Back Pain 43 (16.9) 1 (0.4)

Novartis Confidential Page 30
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Preferred termLDK378
750mg
N=255
All Grades Grade 3/4
n (% ) n (% )
Headache 41 (16.1) 3 (1.2)
Weight Decreased 39 (15.3) 4 (1.6)
Blood Creatinine Increased 39 (15.3) 0
Pyrexia 38 (14.9) 0
Rash 32 (12.5) 0
Insomnia 31 (12.2) 0
Dyspepsia 26 (10.2) 1 (0.4)
Hypokalemia 26 (10.2) 11 (4.3)
Dizziness 26 (10.2) 0
Dose reductions due to AEs occurred in 58.4% of patients treated with L DK378 at the 750 mg 
dose; 38.8% of patients had only 1  dose reduction. The most frequent AEs requiring dose 
adjustments or interruptions reported in >5% of the patients were: ALT increa sed, nausea, 
AST increased, vomiting, diarrhea, fatigue, and abdominal pain. AEs leading to study  drug 
discontinuations occurred in 10.2% of patients treated with LDK378 at the 750 mg dose. The 
most frequent AEs leading to study  drug discontinuations were decreased appetite, pneumonia, 
ALP increased, pneumonitis, and respiratory  failure.
Serious adverse events (SAEs) reported in 2% or more of the 255 patients treated at the 
recommended dose of 750 mg were convulsion, pneumonia, interstitial lung disease 
(ILD)/pneumonitis, dyspnea, hypergl ycemia, and nausea. Fatal adverse reactions occurred in 
5% of patients, consisting of: pneumonia (4 patients), respiratory  failure, ILD/pneumonitis, 
pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary 
tuberculosis, cardiac tamponade, and sepsis (1 patient each). Adverse events of special 
interest (AESIs) to be monitored for LDK378 have also been identified and include: 
hepatotoxicity , interstitial lung disease/pneumonitis, QT interval prolongation, bradycardia, 
hypergly cemia gastrointestinal toxicity  (nausea, vomiting and diarrhea) and pancreatitis 
(including lipase and amylase elevations) .For additional details, refer to [Investigator’s 
Brochure].
1.2.1.2.2 Clinical efficacy
LDK378 has demonstr ated potent antitumor activity  in 
patients with advanced, ALK -
rearranged NSCL C (Shaw et al 2013). Among 114 response -evaluable patients with at least 
18 weeks of follow -
up prior to 28 Feb, 2013, or who discontinued study  earlier, and were 
treated with LDK378 doses of 400 mg qd or higher, 66 (58%) patients have responded ( Table 
1-2). In addition, the response rate to LDK378 is similar regardless of prior ALK inhibitor 
therap y. In patients with NSCL C treated at ≥400 mg qd, who had previously  received 
crizotinib, the response rate was 57%, and in those who had not previously received crizotinib 
it was 60%. Post-baseline tumor measurements are available fo
r 104 of the 114 response 
evaluable patients. A waterfall plot display ing the maximum decrease from baseline in the 
sum of the longest tumor diameters (Figure 1-1) shows that the large majority  of patie nts 
treated with LDK378 had a reduction in tumor burden. The median duration of response in 

Novartis Confidential Page 31
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
patients who responded and were treated at ≥400 mg qd was 8.2 months (95% CI: 6.9, not 
estimable), and 71% had a duration of response of 6 months or longer.
Table 1-2 Study  CLDK378X2101 Response Rate
Response rate (RECIST v1.0) N CR
n (% )CR + PR
n (% )
All NSCLC, ≥400 mg/d 114 1 (1) 66 (58)
NSCLC, at 750 mg 78 0 47 (60)
ORR b y prior crizotinib treatment
NSCLC prior crizotinib, ≥400 mg/d 79 1 (1) 45 (57)
NSCLC prior crizotinib, 750 mg/d 49 0 29 (59)
NSCLC crizotinib naive, ≥400 mg/d 35 0 21 (60)
NSCLC crizotinib naïve 750 mg/d 29 0 18 (62)
Figure 1-1 Waterfall plot of reduction in sum of longest tumor diameters
The available data from the ongoing phase I study  indicate that LDK378 has substantial 
antitumor activity in patients with ALK -rearranged NSCL C whose disease has failed 
crizotinib therapy or who are naïve to crizotinib therapy .
1.2.1.2.3 Clinical pharmacodynamics
Data are not available from the ongoing clinical study .

Novartis Confidential Page 32
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
1.2.1.2.4 Clinical pharmacokinetics

Novartis Confidential Page 33
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
1.3 Risks and benefits
Overall benefit -risk 
LDK378 dosed at 750 mg once daily  has remarkable anti-tumor activity and induces a high 
rate of rapid and durable responses and prolonged PFS in patients with advanced, ALK -
positive NSCLC, regardless of whether they had been previousl y treated with an ALK 
inhibitor or were ALK inhibitor naïve. The substantial anti-tumor activity  and resulting 
clinical benefit combined with the clinically  manageable safet y profile of LDK378 strongl y 
suppor t a positive benefit/risk balance for ALK -positive NSCL C patients. 
Efficacy
Patients with prior ALK inhibitor treatment: ALK-positive NSCL C patients previously 
treated with LDK378 who have progressed and patients intolerant to crizotinib have no 
effective treatment options, have a dismal prognosis, and represent a population with a high 
unmet medical need. In ALK-positive NSCL C patients failing treatment with crizotinib, 
independent from the resistance mechanism involved, ALK translocation is still present and is 
still the oncogenic driver in almost all of the cases. Chemotherapy  is not expected to provide a 
meaningful clinical benefit in these patients, as was recentl y demonstrated in a Phase III study  
(PROFILE 1007) of crizotinib vs. chemotherap y in the s econd -line setting ( Shaw et al 2013 ).
In ALK -positive NSCL C patients previously  treated with an ALK inhibitor and multiple prior 
lines of anti-neoplastic therap y, based on an independent review of tumor assessments, as of 
, the response rate was 45.1% (95% CI: 37.1 - 53.3) and the median DOR was 
7.1 months (95% CI: 5.6 –NE). The median PFS was 6.7 months (95% CI : 5.5 -7.7) in Study  
[CLDK378X2101] . The median PFS is similar (overlapping 95% CIs) to that reported for 
crizotinib in the second -line setting (7.7 months (95% CI : 6.0 -8.8)) and similar or better than 
that reported for chemotherapy  (4.2 months (95% CI: 2.8 - 5.7) with pemetrexed and 
2.6months (95% CI : 1.6 -4.0) with docetaxel) in the PROFILE 1007 study  (Shaw et al 2013 ) 
for patients with locall y advanced or metastatic ALK -positive NSCL
C who had received prior 
treatment with one platinum
-containing chemotherap y regimen. Therefore , LDK378 fulfills 
an existing unmet medical need.
The efficacy  of LDK378 seen in Study  [CLDK378X2101] is highly  encouraging in heavil y 
pretreated patients with advanced disease, high tumor burden (including a high proportion of 
brain metastases at baseline ), limited available therapeutic options, and dismal prognoses 

Novartis Confidential Page 34
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
following prior ALK -targeted therapies, where the only options are chemotherap y and best 
supportive care.
 
 
 
 
 
Safety
The safet y profile of LDK378 is manageable ( Section 1.2.1.2 ), with a low rate of AEs leading 
to discontinuation. Furtherm ore, patients’ perception of their quality  of life was maintained or 
slightly  improved with LDK378 treatment. The most common AEs were gastrointestinal 
(diarrhea, nausea, vomiting); increases in transaminases, decreased appetite, fatigue; 
abdominal pain, and constipation were also seen in ≥ 25% of patients. These AEs can be 
managed with symptomatic treatment and/or dose reductions or interruptions; only 8.8% of 
patients 
discontinued study  drug due to an AE. No clinically  meaningful differences in the 
safet yprofile were observed between ALK -positive NSCL C patients previously  treated with 
an ALK inhibitor and ALK inhibitor naïve patients.
The risks identified with LDK378 treatment include hepatotoxicity , interstitial lung disease 
(ILD)/pneumonitis, QT interva l prolongation, brady cardia, hypergl ycemia, gastrointestinal 
toxicity  (nausea, vomiting and diarrhea) and pancreatitis (including lipase and amylase 
elevations) (Section 8.1.3). These risks can be manag ed and ameliorated by early diagnosis 
and dose adjustment/interruption, or permanent discontinuation.
 
Risk management during study  conduct
In order to manage the risks associated with LDK378 treatment, specific dose modifications 
and stopping rules during study  conduct are described in the protocol. For patients who do not 
tolerate the initial protocol -specified dose, dose adjustments are provided in order to allow the 
patients to continue the study  treatment (Section 6.2and Table 6-2). Patients whose treatment 
is temporaril y interrupted or permanently  discontinued due to a study  drug related AE 
or an 
abnormal laboratory  value must be followed until resolution or stabilization of the event, 
whichever comes first, including all stud y assessments appropriate to monitor the event. 
Patients may voluntaril y withdraw from study  treatment at any time or on the advice of the 
investigator if he/she believes that continuation would be detrimental to the patient’s well-
being. When the patient discontinues from study  treatment, an End of Treatment (EOT) visit 
must be performed as soon as possible and within 7 day s of the last dose of LDK378. Patients 
will also be contacted for the safet y follow -up 30 days after their last dose of LDK378 to 
determine if they  have experienced an y new AEs and/or to follow resolution of ongoing AEs.

Novartis Confidential Page 35
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
Detailed information on allowed and prohibited concomitant medications is provided in 
Section 6.3. In vitro drug metabolism studies show that the metabolism of LDK378 is 
mediated by CYP3A4/5. Appendix 1 contains several tables listing medications that are 
prohibited, permitted or to be used with caution during treatment with LDK378. Prohibited 
medications should be discontinued at least 1 week prior to the start of treatment with 
LDK378 (see exclusion criteria #8).
Recommended guidelines for prophy lactic or supportive treatment for expected toxicities, 
including management of study -
drug induced AEs, are extensivel y described in Section 6.2.4.
Furthermore, regarding adverse events of special interest (see Section 8.1.3 ): 
Hepatotoxicity : cases of hepatotoxicity  occurred in less than 1% of patients treated with 
LDK378 in clinical studies. Increases to grade 3 or 4 ALT elevations were observed in 
25% of patients receiving LDK378. Concurren t elevations in AL T >3xULN and total 
bilirubin >2xUL N, with normal alkaline phosphatase, occurred in less than 1% of patients 
in clinical studies. The majority  of cases were manageable with dose interruption and/or 
dose reduction. Few events required disco ntinuation of LDK378. Patients will be closely  
monitored by  regular laboratory  testing and related signs and s ymptoms. Risk to patients 
will also be minimized by  restricting study  enrollment to subjects with laboratory  values 
for AST, ALT, ALP and bilirubi n below certain thresholds (see inclusion criteria #7). 
Interstitial lung disease/pneumonitis: severe, life -threatening, or fatal interstitial lung 
disease (ILD)/pneumonitis have been observed in patients treated with LDK378 in clinical 
studies. Most cases improved or resolved with interruption of LDK378. Patients will be 
monitored for s ymptoms such as shortness of breath, cough or fever. Risk to patients will 
be minimized by  excluding from study  enrollment any  patient with a history  of interstitial 
lung d isease or interstitial pneumonitis, including clinically  significant radiation 
pneumonitis (i.e., affecting activities of daily  living or requiring therapeutic intervention) 
(see exclusion criteria #19).
QT interval prolongation: QTc prolongation has been observed in clinical studies in 
patients treated with LDK378, which may  lead to an increased risk for ventricular 
tachyarrh ythmias (e.g., Torsade de pointes) or sudden death. A pharmacokinetic anal ysis 
suggested that LDK378 causes concentration -dependent i ncreases in QTc. Repeated ECG 
tracings will be performed throughout the stud y to closely monitor cardiovascular safet y. 
Risk to patients will also be minimized by  excluding from study  enrollment those patients 
with clinically  significant, uncontrolled hear t disease and/or a recent cardiac event (within 
6 months), including a corrected QT (QTcF) > 470 ms using Fridericia’s correction on the 
screening ECG (see exclusion criteria #5).
Brad ycardia: as ymptomatic cases of brady cardia have been observed in patients treated 
with L DK378 in clinical studies. Repeated ECG tracings will be performed throughout the 
study  to closel y monitor cardiovascular safet y. Risk will also be minimized by monitoring 
concomitant use of other agents known to cause brady cardia (e .g., beta -blockers, non-
dihydropyridine calcium channel blockers, clonidine, and digoxin) to the extent possible. 
Heart rate and blood pressure will also be monitored regularly  during the study .
Hypergl ycemia: events of hypergl ycemia (all grades) have been reported in less than 10% 
of patients treated with LDK378 in clinical studies; 5% of patients reported a grade 3/4 
event. The risk of h ypergly cemia was higher in patients with diabetes mellitus and/or 

Novartis Confidential Page 36
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
concurrent steroid use. Patients will be closely  monit ored throughout the study  for any  
signs and s ymptoms related to elevated blood glucose levels.
Gastrointestinal toxicity : diarrhea, nausea, and vomiting have been very  commonly  
reported; 12.2% of patients reported a grade 3/4 event of diarrhea, nausea, or vomiting. 
Risk to patients will be minimized during the study  by closely  monitoring sy mptoms and 
managing patients using standards of care, including anti -diarrheals, anti -emetics, or fluid 
replacement, as indicated.
Pancreatitis (including lipase and am ylase elevations): in most cases, pancreatic enz yme 
elevations have been mild to moderate, and have typically  reversed with interruption of 
LDK378. Few patients have experienced pancreatitis with severe upper abdominal pain. 
Patients will be monitored closel y for an y related signs and s ymptoms.
Conclusion
The outstanding anti-tumor activity  and resulting clinical benefit combined with the 
manageable safet y profile of LDK378 strongl y support a positive benefit -risk balance for 
ALK -positive NSCL C patients, rega rdless of whether the patients had received prior ALK 
inhibitor treatment or not.  
The risk to subjects in this trial will be minimized and managed by compliance with the 
eligibility  criteria, close clinical monitoring, dose modifications/interruptions and permanent 
discontinuation as required. There may be unforeseen risks with LDK378 which could be 
serious. Refer to the Investigator’s Brochure for additional information regarding the safet y 
profile of LDK378. 
2 Rationale
2.1 Stud y rationale and purpose
ALK rearrangement is a relativel y rare event in NSCL C with a frequency  of 2-8% 
(Scagliotti 2012; Takeuchi 2009; Soda 2007). This rearrangement results in aberrant ALK 
activation. ALK fusion proteins possess potent oncogenic activity  both in vitro and in vivo. 
This activity  can be effectively  blocked b y small -molecule inhibitors that target ALK.
The purpo
se of this phase II study is to evaluate the antitumor activity  and safet y profile of the 
novel ALK inhibitor LDK378 when used as a single agent in patients with ALK-rearranged 
locally  advanced or metastatic NSCL C who have not been pretreated with crizotin ib.

Novartis Confidential Page 37
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
2.2 Rationale for the study  design
This is a prospective, multi- center, open -label, single arm, phase II study  with two-stage 
design to evaluate the efficacy  and safet y of single -agent LDK378 i
n patients with ALK -
rearranged NSCL C not previously  treated with crizotinib. Patients may have received up to 
three prior lines of cytotoxic chemotherapy. In such cases, patients must have progressed 
during or after the chemotherap y regimen received prior to the first dose of LDK378. Patients 
will also be eligible for the study  if they have never been treated with chemotherap y for their 
NSCL C.
The primary  objective is to demonstrate the antitumor activity  of LDK378 in this population. 
The primary  measure ofantitumor activity  is the ORR according to RECIST 1.1 and will be 
estimated based on investigator assessment. In addition, there will be an independent 
radiological review by a blinded independent review committee (BIRC). Response rate is an 
appropriate primary  endpoint that can be adequately  assessed in the context of this single arm 
phase II trial. A high ORR may predict clinical benefit in this rare population of patients with 
ALK -rearranged NSCLC. Indeed, crizotinib was approved by certain Health Authorities in 
this indication based on data from two single arm trials using ORR based on investigator 
assessment as primary  endpoint. Data on ORR will be supplemented with data on duration of 
response (DOR) and time to response (TTR).
Based on the data availa ble with LDK378 in crizotinib naïve patients in the ongoing phase I 
study  at the time of the study  design, the present study  will use a two-stage design. The Data 
Monitoring Committee will evaluate the ORR data from Stage 1 and, based on pre-specified 
response criteria (see Section 10.7), will make the recommendation whether to proceed to 
Stage 2 or stop the trial.

Novartis Confidential Page 38
Amended Protocol Version 04 (Clean ) Protocol No. CLDK378A2203
The study  will also assess progression- free survival (PFS), overall survival (OS) and impact 
on Patient Reported Outcomes (PROs) with LDK378 treatment. These endpoints are 
considered to be important supportive endpoints to better assess the potential clinical benefit 
of LDK378. In addition an evaluation of the activity  of LDK378 on brain metastase s will be 
included as a secondary  objective in this study .
Safety  will be monitored throughout the course of the study .
2.3 Rationale for dose and regimen selection
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.

Novartis Confidential Page 39
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Refer to Section 10.4 .
To demonstrate the antitumor activity of LDK378, as 
measured by overall response rate (ORR) to LDK378 by 
investigator assessmentORR per RECIST 1.1 calculated as the proportion of patients with a best 
overall response defined as complete response or partial response (CR+PR) 
as assessed by investigator
Key secondary Refer to Section 10.5.1 .
To evaluate response related endpoints as assessed by 
investigator and Blinded Independent Review Committee 
(BIRC):
1.Duration of response (DOR)
2.Disease control rate (DCR)
3.Time to Response (TTR)
4.Overall intracranial response rate (OIRR)
And to assess:
5.ORR by BIRC assessmentThe following endpoints will be evaluated by investigator assessment and 
BIRC per RECIST 1.1:
1.DOR, calculated as the time from the date of the first documented CR or 
PR to the first documented progression or death due to any cause
2.DCR, calculated as the proportion of patients with best overall response 
of CR, PR, or SD
3.TTR, calculated as the time from first dose of LDK378 to first 
documented response (CR+PR)
4.OIRR calculated as the ORR (CR+PR) of lesions in the brain for patients 
who have measureable disea se in the brain at baseline 
And:
5.ORR (CR+PR) per RECIST 1.1 as assessed by BIRC
Other secondary Refer to Section 10.5.2 .
1.To evaluate the safety profile of LDK378
2.To evaluate progression -free survival (PFS)
3.To evaluate overall survival (OS)1.Adverse events and laboratory abnormalities
2.PFS, defined as time from first dose of LDK378 to progression or death 
due to any cause, as assessed by BIRC and investigator assessment
3.OS, defined as time from f irst dose of LDK378 to death due to any cause

Novartis Confidential Page 40
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Objective Endpoint Anal ysis

Novartis Confidential Page 41
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
4 Study  design
4.1 Description of study  design
This is a single -arm, open -label, two-stage, multicenter, phase II study  in which the efficacy 
and safet y of LDK378 will be evaluated in patients with locally  advanced or metastatic 
NSCL C harboring a confirmed ALK rearrangement, defined as 15% or more positive lung 
tumor cells as assessed by the FDA -approved FISH test (Abbott M
olecular Inc.) using Vysis 
break -apart probes.
Overview  of the study design
Patients will be pre-screened to test for ALK positivity . The test to confirm ALK 
rearrangement must be performed either using archival tissue or, preferably , using a new 
biopsy  prior to study  entry according to the above criteria, i.e. with the FDA -approved Vysis 
ALK break -apart FISH assay . The test will be performed at a Novartis designated central 
laboratory .
After confirmation of ALK positivity , the study begins with a screening period to assess 
eligibility , up to and including 28 day s prior to the first dose of LDK378.
Patients must not have received prior crizotinib. Patients may  have been treated with cy totoxic 
chemotherap y (up to 3 lines). In such cases, patients must have progressed during or after the 
last chemotherap y regimen received prior to the first dose of LDK378. Patients will also be 
eligible for the study  if they  have never been treated with chemotherapy  for their NSCL C.
The study  will use a Simon’s optimal two -stage design. Stage 1 will consist of 43 patients and 
their data up to 6 cycles of treatment unless a patient has discontinued treatment earlier or a 
confirmed response to treatment has been observed prior to completing 6 cy cles. The trial will 
be stopped atStage 1 for futility  if 16 or fewer responses are observed. If at the time that the 
last patient is enrolled to Stage 1 a minimum of 17 responses have not yet been observed, 
accrual may be temporarily  suspended during the analysis of Stage 1. The Data Monitoring 
Committee will periodically  review response data and will make the appropriate 
recommendation regarding transition into Stage 2 or stopping enrollment (see Section 8.6).
Stage 2 will include an additional 62 
patients. The primary  analysis will occur when all 105 
patients have completed 6 cycles of treatment or discontinued treatment earlier. Patients will 
follow the study  design shown in Figure 4-1and have study  assessments as described in 
Section 7.
The treatment period begins on Day 1
 of Cycle 1. All patients will be treated with LDK378, 
administered orall y, at a starting dose of 750 mg. A total of approximately  105 patients will be 
enrolled in the study . Patients will take LDK378 once daily , at approximately  the same time 
each day.  
 Treatment with LDK378 will continue until the 
patient experiences unacceptable toxicity  that precludes further treatment, discontinues 
treatment at the discretion of the patient or investigator, starts a new anti-cancer therap y or 
dies. If the patient experiences RECIST -defined progressive disease (PD) on LDK378 as 

Novartis Confidential Page 42
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
assessed by the investigator, treatment with the study  drug may be continued if, in the 
judgment of the investigator, there is still evidence of clinical benefit. These patients w ill be 
counted as PD for ORR, DOR, DCR and PFS calculations.
Assessments of tumor response and progression will be performed every  8 weeks (i.e. every  2 
cycles), starting from the first day of treatment with LDK378. This schedule of tumor 
assessment every  8 weeks must continue regardless of dose interruptions. Tumor assessment 
should continue until:
For patients who experience PD as assessed b y the investigator, tumor assessments should 
continue every  8 weeks until LDK378 is permanently  discontinued (i.e. i f the patient 
continues treatment with LDK378 after PD, tumor assessments should continue until 
LDK378 is permanently discontinued).
For patients who discontinue treatment in the absence of PD, tumor assessments should 
continue every  8 weeks from the EOT visit until PD is assessed by  the investigator.
Tumor evaluations will alway s cease if the patient withdraws consent (unless the patient 
agrees to continue efficacy  assessments in absence of dosing with LDK378, see Section 
7.1.4.1), or dies.
All tumor imaging assessments will be submitted for independent radiological assessment of 
response b y a Blinded Independent Review Committee (BIRC).
Clinical and laboratory  assessments will be performed as described in Section 7.
When the patient discontinues from study  treatment an End of Treatment (EOT) visit must be 
performed as soon as possible and within 7 days of the last dose of LDK378. Patients will be 
contacted for the safet y follow -up 30 day s after their last dose of L DK378 to determine if they 
have experienced an y new AEs and/or to follow resolution of ongoing AEs.
Following the end of tumor assessments, the Study  Phase Completion Disposition eCRF must 
becompleted. Patients will be contacted every  3 months to obtain information pertaining to 
survival status until death, loss to follow -
up, withdrawal of consent to survival follow -up, or 
the end of the study  (as defined in Section 4.3). Patients do not need to visit the clinic during 
the survival follow -
up.
4.2 Tumor sample requirements
There are two parts to the tumor sample requirements of the trial:
In order to test ALK status at the molecular pre -screenin g stage, all patients must have a 
tumor tissue sample available, preferably  as a newly  obtained tumor biops y or, if a new 
biopsy  is not obtainable or the patient does not agree, an archival tumor biopsy  collected 
either at the time of NSCLC diagnosis or an y time since. All available tumor tissue, 
whether new biopsy or archival sample, should be sent to the central laboratory  at pre -
screening.
If a new biopsy  was not collected at molecular pre -screening, patients must be asked at 
screening if they  are willin g to provide a new tumor tissue biopsy  (although participation 
is optional). Consent for this sample must be obtained via the additional optional I nformed 
Consent Form (ICF).  

Novartis Confidential Page 43
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
 
4.2.1 Archival tissue
Acceptable archival tumor tissue may consist of a formalin fixed paraffin embedded (FFPE) 
NSCL C tumor block or at least 7, preferabl y 15, slides 5 µmthick. If a tumor block is 
provided, the remaining tissue will be returned to the site upon request. Note: Cytology 
samples from pleural fluid can not be used for testing ALK status.
4.2.2 New biopsies
Preferably , a new tumor biopsy  should be obtained at pre-screening if the patient agrees on 
the molecular pre -screening consent form.
4.2.3 Tumor samples analyses
Any tumor tissue sample obtained will be utilized for two purposes:
Determination of ALK status using the FDA -approved Vysis ALK break- apart FISH assay  
(Abbott Molecular Inc.): the test to assess ALK rearrangement will be performed by  a 
Novartis designated central laboratory . The test will be performed on the new tumor 
biopsy  obtained at pre -screening if the patient has c onsented to the biops y. If a new biopsy 
is not available, the test to determine ALK status will be performed using the archival lung 
tumor tissue. Note: Cy tology  samples from pleural fluid can not be used for testing ALK 
status.

 
 

Novartis Confidential Page 44
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Figure 4-1 Study  design
4.3 Definition of end of the study
There will be no interim anal ysis of efficacy . The primary  analysis will occur once all patients 
have completed at least 6 cycles of treatment with LDK378 or have discontinued earlier. At 
this time, the primary  clinical study  report (CSR) will be produced. Following the primary 
analysis time point, the study  will remain open. Patients still being followed on the study  will 
continue as per the schedule of assessments.

Novartis Confidential Page 45
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Following the cut-off date for the analysis reported in the primary  CSR, the study  will remain 
open. Ongoing patients will continue to receive study  treatment and be followed as per the 
schedule of assessments, as long as patients derive benefit from LDK378. The end of study 
defined as the earliest occurrence of one of the following:
At least 75% of patients have died or all patients discontinued from the study .
Other clinical stud ies (e.g. roll-over protocol or other) or patient support program sbecome 
available that can continue to provide LDK378 in this patient population and all patients 
ongoing are eligible to be transferred tothem.
At the end of the stud y, every effort will be made to continue provisio n of study  treatment 
outside this study  through an alternative setting to patients who in the opinion of the 
Investigator are still deriving clinical benefit.
The final analy sis will occur at the end of the study . All available data from all patients up to
this cut -off date will be analy zed and summarized in a final CSR.
4.4 .Earl y study  termination
The study  can be terminated at any time for any reason by Novartis. Should this occur, the 
patient should be seen as soon as possible and the same assessments as for a prematurel y 
withdrawn patient as described in Section 7 should be performed. The investigator may be 
informed of additional procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the patient’s interests. The investigator will be 
responsible for informing I RBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient population
This study  of LDK378 will be conducted in crizotinib -naïve adult p
atients with ALK -
rearranged (as determined by the FDA -approved Vysis ALK break- apart FISH assay ) locall y 
advanced or metastatic NSCL C who are either chemotherap y-naïve or who have been 
previously  treated with cy totoxic chemotherapy  (up to 3 lines).
The investigator or designee must ensure that only patients who meet allof the inclusion and 
none of the exclusion criteria are offered treatment in the study .
See Section 7.1.1 for details on pre- screeni ng procedures.
Patients enrolled in this study  are not permitted to participate in additional parallel 
investigational drug or device studies while on treatment. Rescreening will not be allowed; 
however, laboratory  parameters may be retested within the 28-day screening period for an 
individual patient if such parameters meet an exclusion criterion when initially  tested.

Novartis Confidential Page 46
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteria:
1.Histologicall y or c ytologicall y confirmed diagnosis of stage IIIB or IV NSCL C that 
carries an ALK rearrangement defined as 15% or more positive tumor cells as assessed b y 
the FDA -approved FI SH test (Abbott Molecular Inc.) using Vy sis break -apart probes. 
Patients will be pre
-screened to test for ALK positivity . The test to confirm ALK 
rearrangement must be performed either using archival tissue or, preferabl y, using a new 
biopsy  prior to the first dose of LDK378 according to the above criteria, i.e. with the 
FDA -approved Vy sis ALK break -apart FISH assay. The test will be performed at a 
Novartis designated central laboratory .
2.Age 18 years or older at the time of informed consent.
3.Patients must have stage IIIB or IV NSCL C at the time of study  entry .
4.Patients must be chemotherap y-naïve or ha ve received up to 3 lines of prior cy totoxic 
chemotherap y to treat their stage IIIB or IV NSCLC. I f patients received chemotherap y, 
such patients must have progressed during or after the last chemotherapy  regimen received 
prior to the first dose of LDK378.
Prior erlotinib or gefitinib will not count as a line of cy totoxic chemotherapy  (i.e. 
patients may  have received prior treatment with these drugs)
(Neo -)adjuvant cy totoxic chemotherap y will count as one prior line of treatment if 
relapse occurred within 1 2 months from the end of the adjuvant cy totoxic 
chemotherap y.
Note : A cy totoxic chemotherapy  line in locall y advanced or metastatic (stage IIIB or 
IV) disease is defined as an anticancer regimen that contains at least 1 cy totoxic 
chemotherap y agent and is given for 21 day s or more. If a cy totoxic chemotherap y 
regimen was discontinued for a reason other than disease progression and lasted less 
than 21 day s, then this regimen does not count as a prior line of chemotherapy .
5. Patients must have a tumor tissue sa mple available, preferabl y being a new biopsy  but 
otherwise being an archival sample collected either at the time of diagnosis of NSCL C or 
any time since, for assessing ALK rearrangements using the FDA -approved Vy sis ALK 
break -apart FISH assay  (see Section 4.2).
6.Patients must have recovered from all toxicities related to prior anticancer therapies to 
grade ≤ 2 (CTCAE v 4.03). The exception to this criterion is for patients with grade 2 
nausea/vomiting an d/or grade 2 diarrhea despite optimal supportive therapy  who will not 
be allowed to participate in the study . Patients with any  grade of alopecia are allowed to 
enter the stud y.
7.Patients must meet the following laboratory  values at the screening visit:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelets ≥ 75 x 109/L
Hemoglobin (Hgb) > 8 g/dL
Calculated creatinine clearance (using Cockcroft -Gault formula) > 30 mL/min

Novartis Confidential Page 47
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Total bilirubin < 1.5 x ULN (Upper limit of normal), except for patients with 
Gilbert’s sy ndrome, who may  only be included if total bilirubin < 3.0 x ULN or direct 
bilirubin < 1.5 x UL N
Aspartate transaminase (AST) < 3 x UL N, except for patients with liver metastasis, 
who are onl y included if AST < 5 x UL N
Alanine transaminase (ALT) < 3 x UL N, except for patients with liver metastasis, 
who are onl y included if AL T < 5 x UL N
Patients must have the following laboratory  values within the laboratory  normal limits 
or corrected to within normal limits with supplements during screening:
Potassium
Magnesium 
Phosphorus 
Total calcium (corrected for serum albumin) 
8.Life expectancy  ≥ 12 weeks.
9.World Health Organization (WHO) performance status 0 -
2.
10. At least one measurable lesion as defined b y RECIST 1.1. A previously  irradiated site 
lesion may  only be co unted as a target lesion if there is clear sign of progression since the 
irradiation.
11.Written informed consent for the main study  must be obtained prior to any  screening 
procedures. If consent cannot be expressed in writing, it must be formall y documented and 
witnessed, ideall y via an independent trusted witness.
12.Willingness and ability  to comply  with scheduled visits, treatment plans, laboratory  tests 
and other stud y procedures.
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the f ollowing criteria:
1.Prior treatment with crizotinib, or any  other ALK inhibitor investigational agent, for 
NSCL C
2.Patients with sy mptomatic central nervous s ystem (CNS) metastases who are 
neurologicall y unstable or have required increasing doses of steroids within the 2 weeks 
prior to study  entry  to manage CNS sy mptoms.
3.History  of carcinomatous meningitis.
4.Presence or history  of a malignant disease other than NSCL C that has been diagnosed 
and/or required therap y within the past 3 y ears. Exceptions to this exc lusion include the 
following: completel y resected basal cell and squamous cell skin cancers, and completel y 
resected carcinoma in situ of an y type.
5.Clinically  significant, uncontrolled heart disease, such as:
Unstable angina within 6 months prior to screening
Myocardial infarction within 6 months prior to screening
History  of documented congestive heart failure (New York Heart Association 
functional classification III -IV)

Novartis Confidential Page 48
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Uncontrolled h ypertension defined b y a S ystolic Blood Pressure (SBP) ≥ 160 mm Hg
and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without anti -
hypertensive medication. I nitiation or adjustment of antihy pertensive medication (s) is 
allowed prior to screening
Ventricular arrh ythmias
Supraventricular and nodal arrh ythmias not controlled with medication
Other cardiac arrh ythmia not controlled with medication
Corrected QT (QTc) > 470 msec using Fridericia correction (QTcF) on the screening 
ECG (as mean of triplicate ECG)
6.Thoracic radiotherap y to lung fields ≤ 4 weeks prior to star ting the stud y treatment or 
patients who have not recovered from radiotherap y-related toxicities. For all other 
anatomic sites (including radiotherap y to thoracic vertebrae and ribs), radiotherap y ≤ 2 
weeks prior to starting the study  treatment or patients who have not recovered from 
radiotherap y-related toxicities. Palliative radiotherap y for bone lesions ≤ 2 weeks prior to 
starting stud y treatment is allowed.
7.Major surgery  (e.g., intra -thoracic, intra- abdominal or intra -pelvic) within 4 weeks prior (2 
weeks for resection of brain metastases) to starting study  drug or who have not recovered 
from side effects of such procedure. Video -assisted thoracic surgery (VATS) and 
mediastinoscopy  will not be counted as major surgery  and patients can be enrolled in the 
study  ≥1 week after the procedure.
8.Patients receiving treatment with medications that meet one of the following criteria and 
that cannot be discontinued at least 1 week prior to the start of treatment with L DK378 
and for the duration of the study :
Strong i nhibitors or strong inducers of CYP3A4/5 ( Appendix I )
Medications with a low therapeutic index that are primarily  metabolized by 
CYP3A4/5, CYP2C8 and/or CYP2C9 ( Appendix I )
Medications with a known risk of prolonging the QT interval or inducing Torsades de 
Pointes ( Appendix I )
9.Impairment of GI function or GI disease that may  significantl y alter the absorption of 
LDK378 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or 
malabsorption sy ndrome).
10.
Patients who are currently  receiving treatment with warfarin sodium (Coumadin®) or any  
other coumarin- derivative anticoagulants.
11.Patients receiving unstable or increasing doses of corticosteroids. If patients are on 
corticosteroids for endocrine deficiencies or tumor-associated s ymptoms other than CNS 
related, dose must have been stabilized (or decreasing) for at least 5 day s before first d ose 
of study  treatment.
12.Patients receiving treatment with any  enzy me-inducing anticonvulsant ( Appendix I ) that 
cannot be discontinued at least 1 week before first dose of study  treatment, and for the 
duration of the study . Patients on non -enzy me- inducing anticonvulsants are eligible.
13.Investigational agents within 4 weeks or ≤ 10 x half -life of the agent (whichever is longer) 
before first dose of stud y treatment.

Novartis Confidential Page 49
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
14.Pregnant or nursing (lactating) women, whe re pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.
15.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they are using highly  effective contraception during the study  
and for 30 day s after stopping treatment. Highly effective contraception is defined as any  
of:
1.Total abstinence: when this is in line with the preferred and usual lifest yle of the 
subjec t. [Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception].
2.Sterilization: have had surgical bilateral oophorectomy  (with or without hysterectom y) 
or tubal ligation at least six weeks before taking study  treatment. In case of 
oophorectom y alone, only when the reproductive status of the woman has been 
confirmed b y follow up hormone level assessment.
3.Male partner sterilization (with the appropriate post -vasectom y docum entation of the 
absence of sperm in the ejaculate). [For female subjects on the study  the vasectomized 
male partner should be the sole partner for that patient].
4.Use of a combination of any  twoof the following (a+b or a+c or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception.
b.Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS)
c.Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal s uppository .
In case of use of oral contraception women should have been stable on the same 
pill for a minimum of 3 months before taking study treatment.
16.Sexually  active males must use a condom during intercourse while taking the drug and for 
3 months after stopping LDK378 treatment and should not father a child in this period. A 
condom is required to be used also by  vasectomized men in order to prevent delivery  of 
the drug via seminal fluid.
17.Other severe, acute, or chronic medical or ps ychiatric conditions including uncontrolled 
diabetes mellitus or laboratory  abnormalities that in the opinion of the investigator may  
increase the risk associated with study  participation, or that may  interfere with the 
interpretation of stud y results.
18.Patients with known hy persensitivity  to an y excipients of LDK378 (microcry stalline 
cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate).
19.History  of interstitial lung disease or interstitial pneumonitis, including clinically  
significant radiation pn eumonitis (i.e., affecting activities of daily  living or requiring 
therapeutic intervention) .

Novartis Confidential Page 50
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6 Treatment
6.1 Stud y treatment
For this study , the term “investigational or study  drug” refers to LDK378. All dosages 
prescribed and dispensed to the patient and all dose changes during the study  must be 
recorded on the Dosage Administration Record eCRF.
LDK378 will be provided and supplied by Novartis. LDK378 is supplied as 150 mg hard 
gelatin capsules as individual patient supply , packaged in bottles. LDK378 will be dosed on a 
flat scale of mg/day  and not be adjusted to body  weight or body  surface area.
A complete cy cle of treatment is defined as 28 days of once dail y treatment of LDK378.
6.1.1 Dosing regimen
LDK378 will be administered orally  once daily  at a dose of 750 mg 
on a continuous dosing 
schedule. A complete cycle of treatment is defined as 28 days of once daily  treatment of 
LDK378. The investigator must instruct the patient to take the study drug exactly  as 
prescribed.
 
 
 
 
Patients should take L DK378 on an empty stomach (i.e. fast from food and drink, except 
water) at least 1 hour before or 2 hours after a light meal.
Each dose of LDK378 should be taken with a glass of water and consumed over as short a 
time as possible (i.e. not slower than 1 capsule every  2 minutes).
Patients should be instructed to swallow whole capsules and not to chew or open them.
If vomiting occurs during the course of treatment, no re- dosing of the patient is allowed 
before the next scheduled dose.
Patients should be instructed not to make up missed doses or partial doses (i.e. when the 
entire dose is not taken as instructed). A missed or partial dose will be defined as a case 
when the full dose is not taken within 8 hours after the approximate time of the usually 
daily  dosing. That day ’s dose (or part remaining dose) shoul d be omitted and the patient 
should continue treatment with the next scheduled dose on the following day .
Table 6-1 Dose and treatment schedule
Study  treatments Pharmaceutical form and 
route of administrationDose Frequency  and/or 
Regimen
LDK378 Gelatin capsule for oral use 750 mg (5 x 150 mg capsule) Once daily (28 day cycle)

Novartis Confidential Page 51
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.1.2 Guidelines for continuation of treatment
For guidelines for dose modification of treatment, refer to Section 6.2.
6.1.3 Treatment duration
Patients 
should continue LDK378, and should follow the protocol safety  assessments as 
scheduled, until they  experience any  of the following:
Disease progression (radiologicall y documented according to RE CIST 1.1 as assessed by  
the investigator. Patients who have RECI ST-defined PD as assessed b y the investigator, 
but who, in the opinion of the investigator, have evidence of continued clinical benefit 
from LDK378 may  continue to receive the study  medication . In such cases, these patients 
must continue to be followed for safet y and efficacy assessments as per the schedule of 
assessments.
Unacceptable toxicity  that precludes further treatment
Start of a new anti -cancer therap y
And/or treatment is discontinued at the discretion of the investigator or patient or the 
patient is lost to follow -up.
Patients who permanently  discontinue the study  drug for any reason other than disease 
progression must, if agreeing to further follow -up, continue efficacy  assessments as scheduled 
in the protocol until the time of confirmed disease progression.
After discontinuing LDK378, further treatment for NSCL C is left to the phy sician’s discretion.

Novartis Confidential Page 52
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.1.4 Definition of treatment cy cle
A treatment cycle is defined as 28 calendar days from the start of treatment with LDK378 
(Day  1, cy cle 1) for the purposes of scheduling procedures and evaluations.
6.2 Dose modifications
6.2.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue the study  treatment. Any changes in 
LDK378 administration must be recorded on the Dosage Administration Record eCRF.
LDK378 dose modification guidelines are described in Section 6.2.3 and Table 6-3. Any 
planned 
variance from these guidelines in view of patient safety  must first be discussed with 
the sponsor unless there is an urgent need for action.
All dose modifications, interruptions or discontinuations must be based on the worst 
preceding toxicity  as graded by  the NCI Clinical Toxicity  Criteria (NCI -CTCAE version 4.03).
General guidelines for dose modifications for toxicities other than those list ed 
in Table 6-3
For grade 1 and tolerable grade 2 treatment related toxicities, patients may continue at the 
current dose of study  treatment. For intolerable grade 2 or grade 3 treatment -related toxicit ies, 
dosing should be interrupted until at least resolution to grade 1 followed by dose reduction. 
For any grade 4 toxicity , patients should interrupt study  treatment until resolution to at least 
grade 1, followed by either dose reduction or treatment discontinuation. Treatment with the 
study  drug may subsequently  be continued at a reduced dose level if in the opinion of the 
investigator the patient continues to experience clinical benefit and after discussion with the 
sponsor.
6.2.2 Treatment interruption and tr eatment discontinuation
If the administration of LDK378 is temporarily  interrupted for reasons other than toxicity , 
then treatment with LDK378 will be resumed at the same dose. The same applies if the patient 
experiences an unacceptable toxicity  not specif ically  described in Table 6-3or Section 6.2.3, 
provided this toxicity  resolved to ≤ CTCAE grade 1.If the treatment with LDK378 is withheld 
due to toxicity , scheduled visits and all assessments (including tumor assessments) will 
continue to be performed (with the exception of the dosing of the withheld study  drug), as 
described in 
Table 7 -1.
If thetreatment with LDK378  is withheld 
for more than 28 consecutive days (counting from 
the first day when a dose was missed), due to toxicity , then LDK378 should be permanentl y 
discontinued except in cases where the investigator believes the patient continue s to derive 
clinical benefit. In such cases, treatment with LDK378 may  be resumed at a lower dose.
If the treatment with LDK378 dosing is withheld for more than 28 consecutive day s (counting 
from the first day when a dose was missed) for reasons other than toxicity , then LDK378 
should be permanentl y discontinued. If dosing was withheld for up to 28 consecutive day s for 

Novartis Confidential Page 53
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
reasons other than toxicity , then treatment with LDK378 may be resumed at the same dose if 
the patient is continuing to derive clinical bene fit. Patients who discontinue the study  due to a 
study  drug related AE or an abnormal laboratory  value must be followed as described in 
Section 6.2.4.
All patients will be followed for safet y until 30 
days after the last dose of LDK378. Patients 
whose treatment is temporaril y interrupted or permanentl y discontinued due to an AE or 
abnormal laboratory  value must be followed until resolution or stabilization of the event, 
whichever comes first, including all study  assessments appropriate to monitor the event. 
Detailed guidelines for follow -
up of study  drug related AEs or abnormal laboratory  values 
must be followed as described in Section 6.2.4.
6.2.3 Criteria for LDK378 dose modifications
An LDK378 dose reduction will follow the guidelines described in Table 6 -
2. For each patient, 
a maximum of 3 dose reductions will be allowed. All dose reductions will be in150 mg 
decrements per reduction. The patient must be discontinued from treatment with LDK378 if 
further reduction is necessary .
Once the dose of LDK378 has been reduced due to toxicity , it cannot be re -escalated.
Table 6
-2 Dose reduction steps for LDK378
LDK378 dose levels Dose* and schedule
Starting dose level 750 mg qd continuously
Dose level – 1 600 mg qd continuously
Dose level – 2 450 mg qd continuously
Dose level – 3 300 mg qd continuously **
*Dose reduction should be based on the worst preceding toxicity as per NCI -CTCAE version 4.03
**Dose reduction below 300 mg/day is not allowed. If a dose reduction below 300 mg/day is required, the patient 
should be permanently discontinued from LDK378
Guidelines for dose modification and  dose interruption of L DK378 are described in Table 6 -3.

Novartis Confidential Page 54
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Table 6-3 Criteria for interruption and re -initiation of LDK378 treatment
Dose changes must be recorded on the Dosage Administ ration Record eCRF.
Dose Modifications for LDK378 as specified in Section 6.2.3 .
Worst toxicity  (CTCAE 4.03 Grade)* Dose Modifications for LDK378
HEMATOLOGICAL
Neutropenia (ANC)
Grade 1 (ANC < LLN -1.5 x 109/L)
Grade 2 (ANC < 1.5 and ≥ 1.0 x 109/L)
Grade 3 (ANC < 1.0 and ≥ 0.5 x 109/L)Maintain dose level
Grade 4 (ANC < 0.5 x 109/L)Omit dose until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Febrile neutropenia
(ANC < 1.0 x 109/L, with a single temperature of ≥ 38.3 °C or a sustained 
temperature of ≥ 38 °C for more than one hour )Omit dose until clinically resolved and neutropenia ≤ Grade 2, then 1 dose level
Thrombocy topenia
Grade 1 (PLT < LLN -75 x 109/L)
Grade 2 (PLT < 75 and ≥ 50 x 109/L)Maintain dose level
Grade 3 (PLT < 50 and ≥25 x 109/L) Omit dose until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Grade 4 (PLT < 25 x 109/L) Omit dose until resolved to ≤ Grade 2, then 1 dose level
HEPATIC
Alkaline phosphatase and/or GGT
Isolated elevations of any grade Maintain dose level
Total Bilirubin**
(for patients with Gilbert Syndrome these dose modifications apply to changes in direct [conjugated] bilirubin only)
Grade 1 (> ULN and ≤ 1.5 x ULN) Maintain dose level with LFTs*** monitored as per protocol
Grade 2 (> 1.5 and ≤ 3.0 x ULN) with ALT or AST ≤ 3.0 x ULN Omit dose until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level

Novartis Confidential Page 55
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Grade 3 (> 3.0 and ≤ 10.0 x ULN) with ALT or AST ≤ 3.0 x ULN Omit dose until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, 1 dose level
If resolved in 7 days discontinue patient from LDK378
Grade 4 (> 10.0 x ULN) Permanently discontinue patient from LDK378
AST or ALT
Grade 1 (> ULN and ≤ 3.0 x ULN) Maintain dose level with LFTs*** monitored per protocol
Grade 2 (> 3.0 and ≤ 5.0 x ULN) without total bilirubin elevation to >  2.0x 
ULNMaintain dose level with LFTs*** monitored per protocol
Grade 3 (> 5.0 and ≤ 20.0 x ULN) without total bilirubin elevation to > 2.0 x 
ULNOmit dose until resolved to ≤ Grade 1 (or to baseline) then 1 dose level
Grade 4 (> 20.0 x ULN) without total bilirubin elevation to > 2.0 x ULN Omit dose until resolved to ≤ Grade 1 (or to baseline) then 1 dose level
AST or ALT and concurrent Total Bilirubin
AST or ALT > 3.0 x ULN and total bilirubin > 2.0x ULN in the absence of 
cholestasis or hemolysisPermanently discontinue patient from LDK378 . Refer to Section 6.2.4.2 for additional follow-
up
PANCREATIC
Amylase and/or lipase elevations (in the absence of clinical sy mptoms)
Grade 1 (> ULN and ≤1.5 x ULN) Maintain dose level
Grade 2 ( >1.5 -2.0 x ULN) Maintain dose level
Grade ≥3 (> 2.0 x  ULN) Omit dose until resolved to ≤ Grade 1, then 1 dose level
Note: W ithhold LDK378 for acute onset of new or progressive unexplained abdominal symptoms, such as severe pain or vomiting; perform diagnostic procedures (e.g., 
abdominal CT scan or ultrasound) to exclude pancreatic pathology. 
RENAL
Serum creatinine
Grade 1 (>1 and ≤1.5 x baseline;  >ULN -1.5 x ULN) Maintain dose level
Grade 2 (>1.5 and ≤3.0 x baseline; > 1.5 -3.0 x ULN) Omit dose until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Grade 3 ( >3.0 x baseline ; > 3.0 -6.0 x ULN) Omit dose until resolved to ≤ Grade 1, then 1 dose level
Grade 4 (> 6.0 x ULN) Permanently discontinue patient from LDK378

Novartis Confidential Page 56
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
GASTROINTESTINAL
Diarrhea****
Grade 1 Maintain dose level but adjust anti -diarrhea treatment
Grade 2 (despite maximal anti -diarrheal medication) Omit dose until resolved to ≤ Grade 1, then maintain dose level.
If diarrhea returns as ≥ Grade 2, then omit dose until resolved to ≤ Grade 1, then ↓1 dose 
level
Grade 3 (despite maximal anti-diarrheal medication) Omit dose until resolved to ≤ Grade 1, then ↓1 dose level
Grade 4 (despite maximal anti -diarrheal medication) Omit dose until resolved to ≤ Grade 1, then ↓1 dose level
Nausea*****
Grade 1 or 2 Maintain dose level but adjust anti -emetic treatment
Grade 3 (despite standard anti -emetics) Omit dose until resolved to ≤ Grade 1, then ↓1 dose level
Vomiting*****
Grade 1 Maintain dose level but adjust anti -emetic treatment
Grade 2 (despite standard anti-emetics) Omit dose until resolved to ≤ Grade 1, then maintain dose level.
If vomiting returns as ≥ Grade 2, then omit dose until resolved to ≤ Grade 1, then ↓ 1 dose 
level.
Grade 3 (despite standard anti -emetics) Omit dose until resolved to ≤ Grade 1, then ↓1 dose level
Grade 4 (despite standard anti -emetics) Omit dose until resolved to ≤ Grade 1, then ↓ 1 dose level
METABOLIC
Any Grade hypophosphatemia Treatment with phosphate supplements as clinically indicated and maintain dose level
Persistent hypergl ycemia (glucose >250 mg/dL) despite optimal anti-
hyperglycemic therapyOmit dose until hyperglycemia is adequately controlled, then resume LDK378 at ↓ 1 dose 
level
If adequate hyperglycemic control cannot be achieved with optimal medical management, 
permanently discontinue patient from LDK378
GENERAL DISORDERS
Fatigue (asthenia)
Grade 1 or 2 Maintain dose level
Grade 3 If grade 3 fatigue resolves to Grade 2 in ≤ 7 days, maintain dose level
If grade 3 fatigue lasts > 7 days, omit dose until resolved to ≤ Grade 2 and then dose 
level
CARDIAC

Novartis Confidential Page 57
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Electrocardiogram QT corrected (QTc) interval prolonged
Grade 1 (QTc 450 -480 ms)
Grade 2 (QTc 481 -500 ms)Maintain dose level
Grade 3 (QTc ≥ 501 ms -on at least two separate ECGs) Omit dose until QTc is less than < 481ms, then ↓ 1 dose level
-Assess the quality of the ECG recording and the QT value and repeat if needed
Repeat ECG in 24 hours, or less, as clinically indicated; continue monitoring as clinically 
indicated until QTc < 481 ms
In addition: -Determine the serum electrolyte levels (in particular hypokalemia, 
hypomagnesemia). If abnormal, correct abnormalities before resuming study drug treatment
-Review concomitant medication use for drugs with the potential to increase the risk of drug 
exposure related to QT prolongation
 
After resumption of dosing:
-Repeat ECGs 7 days after dose resumption for all patients who had therapy interrupted 
due to QTc ≥ 501 ms.
Grade 4 (QTc ≥ 501 or > 60ms change from baseline and Torsades de 
pointes or polymorphic ventricular tachycardia or signs/symptoms of 
serious arrhythmia)Permanently discontinue patient from LDK378
Bradycardia
Grade 1 or 2 Omit dose until recovery to asymptomatic bradycardia or to a heart rate ≥60 bpm
Evaluate concomitant medications known to cause bradycardia, and adjust the dose of 
LDK378
Grade 3 
Grade 4 (in patients taking a concomitant medication also known to cause 
bradycardia or a medication known to cause hypotension)Omit dose until recovery to asymptomatic bradycardia or to a heart rate ≥60 bpm
If the concomitant medication can be adjusted or discontinued, resume LDK378 at ↓ 1 dose
level with frequent monitoring
Grade 4 (in patients who are not taking a concomitant medication also 
known to cause bradycardia or known to cause hypotension)Permanently discontinue LDK378

Novartis Confidential Page 58
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
PULMONARY
Notes:
Withhold LDK378 for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever and during diagnostic workup for 
pneumonitis/ILD.
During evaluation of potential grade 2, 3, and 4 pneumonitis, if an infectious etiology is confirmed (i.e., pneumonia) and pn eumo nitis is excluded, then consider 
resuming LDK378 at current dose level after the pneumonia resolves.
PNEUMONITIS
Any Grade treatment -related ILD/pneumonitis Permanently discontinue patient from LDK378
* Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. All dose modifications should be based on the worst preceding toxicity.
**If Grade 3 or 4 hyperbilirubinemia is due to the indirect (non -conjugated) component only, and hemolysis as the etiology has been ruled out as per institutiona l 
guidelines (e.g., review of peripheral blood smear and haptoglobin determination), then ↓1 dose level and continue treatment at the discretion of the investigator.
***LFTs include albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.0 x ULN), alkaline phosphatase and GGT
**** Dose modifications apply to patients who experience diarrhea despite appropriate antidiarrheal medication. This medication should be started at the first sign of 
abdominal cramping, loose stools or overt diarrhea (see Section 6.2.4.4 )
***** Dose modifications apply to patients who experience nausea and/or vomiting despite appropriate antiemetic medication. T his medication should be started at the first 
sign of nausea and/or vomiting (see Section 6.2.4.5 )

Novartis Confidential Page 59
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.2.4 Follow -up for toxicities
An unscheduled visit should be performed in all cases below where toxicity  monitoring is 
recommended more frequently  than defined by  the schedule of assessments ( Table 7 -1).
6.2.4.1 Guidelines for the follow -up of laboratory  hematologic abnormalities
In case of any  occurrence of febrile n eutropenia, neutropenia ≥ grade 3 or thrombocy topenia ≥ 
grade 3, tests must be performed weekl y (or more frequently  if clinicall y indicated) until the 
event resolves to ≤ grade 2. Subsequent monitoring must be performed every  4 weeks. See 
Table 6-4.
Table 6-4 Follo w-up evaluations for selected toxicities
Toxicity Follow -up evaluation*
Investigations 
(hematologic)Febrile neutropenia, neutropenia or thrombocytopenia ≥ CTCAE Grade 3
Test weekly (or more frequent) until ≤ Grade 2
Subsequent monitoring must be performed every 4 weeks
Investigations 
(hepatic)ALT/AST/total bilirubin Grade 2:
Test weekly (or more frequent) unti l ≤ Grade 1
Thereafter, continue to test every 2 weeks (or more frequent) for 2 cycles (8 weeks). If 
no recurrence of ≥ Grade 2 event, continue monitoring every cycle (4 weeks)
ALT/AST/total bilirubin ≥ Grade 3:
Test weekly (or more frequent) until ≤ Grade 1
Thereafter, continue to test every 2 weeks (or more frequent) for 4 cycles (16 weeks). If 
no recurrence of ≥ grade 2 event, continue monitoring every cycle (4 weeks)
Discontinuation due to liver toxicity:
Test weekly (or more frequent) until ≤ Grade 1 o r stabilization
Patients with liver metastasis and grade 2 AST/ALT at baseline, increased monitoring is 
required; for grade 3 or 4 AST/ALT follow guidelines for grade 3 or 4 AST/ALT
Investigations 
(renal)Serum creatinine Grade 2:
Test weekly (or more frequent) until Grade 1
Thereafter, test every cycle (4 weeks)
Serum creatinine ≥ Grade 3:
Test twice weekly (or more frequent) until ≤ Grade 1
Thereafter, test every cycle (4 weeks)
Investigations 
(pancreatic)Amylase/lipase ≥ Grade 3:
Test weekly (or mo re frequently) until ≤ Grade 1. After resumption of dosing, continue to 
test weekly for one additional cycle (4 weeks). If no reoccurrence of ≥ Grade 2 event, 
continue monitoring every cycle (4 weeks)
*Note: this table refers only to the evaluation schedu le to monitor selected toxicities. Refer to Table 6 -3for dose 
modifications required for applicable toxicities
6.2.4.2 Guidelines for the follow -up of laboratory  liver abnormalities
In patients with any clinically  relevant laboratory  liver abnormality , as defined below, hepatic 
toxicity  monitoring must include ALL of the following liver function tests (LFTs): albumin, 
ALT, AST, total bilirubin (fractionated if total bilirubin > 2.0 x ULN), alkaline phosphatase 
and GGT. Note: for patients with Gilbert Syndrome, total and direct bilirubin must be 
monitored, but intensified monitoring applies to changes in direct bilirubin only .
In case of any occurrence of ALT/AST/total bilirubin increase to grade 2 the LFTs must be 
monitored weekl y (or more frequentl y if clinically  indicated) until the event resolves to ≤ 

Novartis Confidential Page 60
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
grade 1. Thereafter monitoring must be continued every  other week (or more frequentl y if 
clinically  indicated) for two additional cy cles (e.g. 8 weeks). Ifthere is no recurrence of grade 
≥2 ALT/AST/total bilirubin elevations during this period, subsequent monitoring must be 
performed every  4 weeks. For patients with liver metastasis and grade 2 AST/AL T at baseline ,
increased monitoring is required; for grade 3 and 4 AST/AL T;follow guidelines for grade 3 
or 4 AST/AL T.
In case of any occurrence of ALT/ AST/total bilirubin increase to grade 3 or 4, LFTs must be 
monitored weekl y (or more frequentl y if clinically  indica ted) until the event resolves to ≤ 
grade 1 or to baseline. Thereafter monitoring must be continued every  other week (or more 
frequentl y if clinically  indicated) for four additional cycles (e.g. 16 weeks). If there is no 
recurrence of ≥ grade 2 ALT/AST/ total bilirubin elevations during this period, subsequent 
monitoring must be performed every  4 weeks.
Patients who discontinue study  treatment due to liver toxicity  must be monitored weekl y (or 
more frequentl y if clinically  indicated) until the event resolves to ≤ grade 1 or stabilization 
occurs (no CTCAE grade change over 4 weeks).
Refer to Table 6 -4.
Patients with transaminase increase combined with total bilirubin (TBIL) increase may be 
indicative of pot ential DILI, and should be considered as clinically  important events. 
The threshold for potential DILI may depend on the patient ’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -
up as outlined 
below:
For patients with normal AL T andAST 
andTBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N 
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or AL T > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as: ALP elevation > 2.0 x ULN with R value (ALT/ALP in x ULN) < 2 in patients without 
bone metastas is, or elevation of AL P liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes the relative pattern of ALT and/or ALP elevation is due to 
cholestatic or hepatocellular liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferably  within 48 hours from 
the awareness of the abnormal r esults. The evaluation should include laboratory tests, detailed 
history , phy sical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc. 
Laboratory tests should include ALT, AST, albumin, creatin ine kinase, total bilirubin, 
direct and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase. 

Novartis Confidential Page 61
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumptio n, history of any  pre-existing liver 
conditions or risk factors, should be collected.
Further testing for acute hepatitis A, B, C or E infection and liver imaging (e g, biliary  tract) 
may be warranted. 
 
 
Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist. 
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medically 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the 
term “potential drug -induced liver injury ”. All events should be followed up with the outcome 
clearl y documented.
6.2.4.3 Guidelines for the follow -up of laboratory  pancreatic abnormalities
In case of any occurrence of lipase or amylase increase to grade 3 or 4, both lipase and 
amylase 
must be monitored weekly  (or more frequently  if clinicall y indicated) until the event 
resolves to ≤ grade 1 (or to baseline). 
After resumption of dosing, monitoring must be continued weekl y (or more frequently  if 
clinically
 indicated) for one additional cy cle (i.e. 4 weeks). If there is no recurrence of ≥ grade 
2 amylase or lipase elevations during this period, subsequent moni toring must be perfor med 
every  4weeks.
Patients who discontinue study  treatment due to pancreatic toxicity  must be monitored weekl y 
(or more frequently  if clinically  indicated) until the event resolves to ≤ grade 1 or stabilization 
occu rs (no CTCAE grade change over 4 weeks). Refer to Table 6 -4.
If amylase and/or lipase elevations are accompanied by new or progressive unexplained 
abdominal symptoms such as severe pain or vomiting, withhold ceritininb, then perform 
diagnosti c procedures (e.g., abdominal CT scan or ultrasound) to exclude pancreatic 
pathology . 
See also dose modification guidelines descried in Table 6
-3.
6.2.4.4 Guidelines for the follow -up of laboratory  renal abnormalities
In case of any occurrence of serum creatinine grade 2, tests must be performed weekl y (or 
more frequently  if clinically  indicated) until the event resolves to ≤ grade 1. Subsequent 
monitoring must be performed every  4 weeks.
In case of an y occurrence of serum creatinine ≥ grade 3, tests must be performed twice weekl y 
(or more frequently  if clinically  indicated) until the event resolves to ≤ grade 1. Subsequent 
monitoring must be performed every  4 weeks. See Table 6-4.

Novartis Confidential Page 62
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.2.4.5 Guidelines for the treatment of study  drug induced diarrhea
The investigator should consider/investigate potential concomitant medication, food or 
comorbidity  driven causes of diarrhea (including infectious causes) and remedy  these causes 
if possible (e.g. discontinuation of concomitant medication, dietary  modification, treatment of 
comorbidity ).
The patient should be monitored for signs of dehy dration and instructed to take preventive 
measures against dehy dration as soon as diarrhea occurs. Antidiarrheal medication must be 
initiated at the first sign of abdominal cramping, loose stools or overt diarrhea. Concomitant 
medication for the treatment of diarrhea should follow local practice and the investigator’s 
best judgment and may follow “the recommended guidelines for the treatment of cancer 
treatment -induced diarrhea” ( Benson et al 2004 ). For example:
For uncomplicated diarrhea (grade 1 or 2 without complicating signs or s ympt oms), 
loperamide given at a standard dose (e.g. initial administration of 4 mg, then 2 mg every  
2-4 hours, maximum of 16 mg/day ), along with oral hy dration and dietetic measures 
should be considered. Note: complicating signs or sy mptoms include: moderate t o severe 
cramping, decreased performance status, fever, neutropenia, frank bleeding or dehy dration.
For complicated diarrhea (all grade 3 or 4, grade 1 -
2 with complicating signs or 
symptoms), management should involve intravenous (IV) fluids, and consider treatment 
with octreotide (at starting dose of 100 to 150 µg sub- cutaneous tid or 25 to 50 µg IV) and 
antibiotics (e.g. fluoroquinolone) should be given.
Dose adaptation of LDK378 in case of treatment related diarrhea must follow the guidelines 
presented a bove in Table 6 -3.
6.2.4.6 Guidelines for the treatment of study  drug induced nausea and 
vomiting
Nausea and vomiting 
are among the most frequently  reported AEs following treatment with 
LDK378 and patients must therefore be closel y monitored for the appearance of these AEs.
The investigator should consider/investigate potential concomitant medication, food or 
comorbidity  driven causes of nausea and/or vomiting and remedy  these causes if possible (e.g. 
discontinuation of concomitant medication, dietary  modification, treatment of comorbidity ).
Individualized supportive and anti-emetic treatment should be initiated, as appropriate, at the 
first signs and/or symptoms of these AEs. In patients with vomiting, the patie nt should be 
monitored for signs of dehydration and instructed to take preventive measures against 
dehy dration.
Concomitant medication for the treatment of nausea and/or vomiting should follow local 
practice and the investigator’s best judgment. For modera te emetogenic drugs, such as 
LDK378, International Guidelines for anti-emetic treatment recommend early treatment with 
5-HT3-receptor antagonists (5 -HT3RAs).
Dose adaptation of LDK378 in case of treatment related nausea and/or vomiting must follow 
the guid elines presented above in Table 6 -3.

Novartis Confidential Page 63
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.2.4.7 Guidelines for the treatment of hypophosphatemia
In the phase I study  [CLDK378X2101] , as of  there were 9 cases of grade 3 
hypophosphatemia in all dose groups, one of which was a DLT that contributed to the MTD 
determination –this patient was able to continue LDK378 at the same dose. One patient in the 
750 mg group had grade 3 hypophosphatemia that resolved after dose adjustment or 
interruption; in the remaining 8 cases, patients were able to continue therapy  without dose 
modification. Hypophosphatemia was a commonly  reported AE (6.3%), regardless of 
relationship to L DK378 treatment.
Therefore, phosphate levels will be checked at baseline and during treatme nt. In cases of 
hypophosphatemia at baseline, phosphate supplements should be started before treatment with 
LDK378. For any grade of hypophosphatemia during the study , treatment with phosphate 
supplements should be given as clinicall y indicated, and the LD K378 dose can be maintained.
6.2.4.8 Recommendations for the monitoring of cases of interstitial lung 
disease (ILD)/pneumonitis toxicity
Monitor patients for pulmonary  symptoms indicative of ILD/pneumonitis. In addition, 
withhold LDK378 for acute onset of new or progressive unexplained pulmonary  symptoms, 
such as d yspnea, cough and fever and during diagnostic workup for pneumonitis/ILD.
Exclude other cases of pneumonitis, and follow dose modification 
guidelines as described in 
Table 6-3. 
6.2.4.9 Anticipated risks and safety  concerns of the study  treatment
Appropriate eligibility  criteria, specific dose modification and stopping rules are included in 
this protocol. Recommended guidelines for prophy lactic or supportive treatment for expected 
toxicities, including management of study -drug induced AEs, e.g., diarrhea are provided in 
Section 6.2.4. Refer to preclinical toxicity  and or clinical data found in the IB.
6.3 Concomitant medications
In general, the use of any concomitant medication/therapy  deemed necessa ry for the care of 
the patient (e.g. anti-emetics, 
anti-diarrheal) is permitted (see Section 6.3.1), except when 
specificall y prohibited (see 
Section 6.3.2).
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications including herbal/natural medications 
(excluding study  treatment and prior antineoplastic treatme nts and blood transfusions), 
surgeries and procedures (including phy sical therapy ) administered within 28 day s prior to the 
first dose of administration of LDK378 through 30 day s after the last dose of LDK378 will be 
recorded in the Concomitant Medications or Surgical and Medical Procedures eCRF, 
respectivel y. Medications include not only physician prescribed medications, but also all 
over-the counter medications, herbal medications (prohibited, see Section 6.3.2.7 ), food or 
vitamin supplements.

Novartis Confidential Page 64
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.3.1 Permitted concomitant therapy
6.3.1.1 Corticosteroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to induce 
CYP3A enzymes, thereby  increasing the risk of reducing LDK378 drug exposure to sub-
therapeutic levels. If possible, systemic corticosteroid treatment should not be given during 
the study , except for:
Topical applications (e.g. rash), inhaled spray s (e.g. obstructive airway s diseases), ey e 
drops or local injections (e.g. intra-articular);
Stable doses of corticosteroid therap y such as dexamethasone and prednisone (e.g. for 
tumor associated s ymptoms) are permitted during the course of the study .
6.3.1.2 Drugs that are metabolized by  CYP450 enzymes
 
 
 
 
 
 
Concomitant treatment of LDK378 with weak inhibitors or inducers of CYP3A4/5 is 
permitted. Caution is advised when LDK378 is co-administered with drugs that are moderate 
inhibitors or inducers of CYP3A4/5 (Table 14-2 of Appendix I).Duration of concomitant 
treatment should be kept as short as possible (e.g. less than 1 week), or completely  avoided 
whenever possible. Patients receiving such medications must be monitored closel y for any 
potentiation of toxicity  or decrease of clinical benefit due to any individual concomitant 
medications, and may require dose titration or adjustment. Note that co-administration of 
LDK378 with strong inhibitors or inducers of CYP3A4/5 is prohibited (refer to Section 
6.3.2.5).
Concomitant treatment of LDK378 with medications known to be metabolized by CYP2C9 
and CYP3A4 is allowed with caution (Table 14
-2 of Appendix I), except for drugs which 
have narrow therapeutic index/sensitive substrates for these CYP isoforms (refer to 
Section 6.3.2.6 andTable 14 -1 of Appendix I ).
6.3.1.3 Non- enzy me inducing anti -epileptic drugs
Non-enzy me inducing anti -epileptic medication (Non- EIAED) is allowed.
6.3.1.4 Palliative radiotherapy and surgery 
Local radiotherap y for analgesic purposes ,or for lytic lesions at risk of fracture may be 
carried out if required. If palliative radiotherap y is initiated after start of study  treatment, the 
reason for its use must be clearl y documented and progression as per RECI ST 1.1 must be
assessed and documented . Patients who develop progressive disease but are still deriving 
clinical benefit from LDK378 therap y, as determined by the Investigator may undergo 

Novartis Confidential Page 65
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
radiotherap y and/or surgical resection as palliative localized therapy  to tre at metastatic lesions. 
LDK378 should be held for at least 4 day s prior to radiotherapy  and at least 1 day  prior to any 
surgery . LDK378 may be resumed ≥3 days after completing radiotherapy  or minor surgery, 
and ≥2 weeks after major surgery .
6.3.1.5 Gastric protection agents
The use of gastric protection agents including antacids, H2-antagonists, and proton pump 
inhibitors (PPIs; Table 14- 2 of Appendix I) is allowed. However, PPIs should be used with 
caution due to the theoretical effects of long-acting pH elevating agents (i.e., prolonged acid 
suppression) on reducing LDK378 absorption. When the concurrent use of a H2 -
antagonist or 
an antacid with LDK378 is necessary , the H2 blocker must be administered 10 hours befo re or 
2 hours after the LDK378 dose, and the antacid must be administered 2 hours before or 2 
hours after the LDK378 dose. Time restrictions for the concurrent use of PPIs and LDK378 
are not applicable due to the long -acting effects of PPI s on gastric pH ( i.e., separation of doses 
will not likely  impact this interaction).
6.3.2 Prohibited concomitant therapy
6.3.2.1 Other anticancer therapy
Anticancer therapy  (chemotherap y, targeted therapy , biologic therapy  or radiation therap y 
[except palliative radiotherap y and palliative surgery  as described in Section 6.3.1.4], and 
anti-cancer surgery ) other than the study  treatment must not be given to patients while they 
are enrolled in the treatment portion of the trial. If such agents are 
required then the patient 
must be permanentl y discontinued from the treatment portion of the study.
6.3.2.2 Other investigational therapies
Other investigational therapies must not be used while the patient is on the study .
6.3.2.3 Warfarin and coum arin derivatives
Warfarin sodium or any other coumarin -derivative anticoagulants are not permitted. LDK378 
is an inhibitor of CYP2C9, the major metabolizing enzyme of warfarin. A clinicall y relevant 
increase in warfarin exposure is possible.
6.3.2.4 Enzy me inducin g anti -epileptic drug (EIA ED)
Use of EIAEDs is not permitted. Refer to Table 14-3 of Appendix Ifor a list of prohibited 
EIAED.
If a patient is currentl y taking an EIAED, he/she must have discontinued 
the EIAED therapy 
for at least 1 week prior to starting stud y drug.
If a patient was previously  on a non-EIAED and needs to permanentl y change anticonvulsant 
agent but cannot change to another non -EIAED, the patient will be taken off LDK378.

Novartis Confidential Page 66
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.3.2.5 Strong CYP3A  inhibitors and inducers
In vitro metabolism studies suggest that oxidative metabolism of LDK378 is predominantl y 
mediated b y CYP3A4/5.
Strong inhibitors or inducers of CYP3A4/5 are prohibited. Patients receiving concomitant 
medications known to strongl y inhibit and/or induce CYP3A4/5 that are deemed medically 
necessary  should be excluded from the study . Refer to Table 14-3 of Appendix Ifor a list of 
these medications. Please note that this list may  not be comprehensive.
6.3.2.6 Medications that are CYP2C9 and CYP3A 4/5 substrates with narrow  
therapeutic index 
LDK378 is a potent inhibitor of drugs metabolized by CYP2C9 and CYP3A4/5 in vitro. 
Because of the potential risk for drug-drug interactions, using medications known to be 
metabolized by these enzy mes and that have a narrow therapeutic index is not permitted 
concomitantly  with LDK378. Refer to Table 14 -3 of Appendix I for a list of these medications. 
Please note that this list may  not be comprehensive.
6.3.2.7 Herbal medications
Herbal preparations/medications are not allowed throughout the study , as a potential drug-
drug interaction is always possible. These herbal medications include, but are not limited to: 
St. John’s wort, Kava, ephedra (ma huang), gingko biloba, dehy droepiandrosterone (DHEA), 
yohimbe, saw palmetto, and ginseng.
Patients should stop using herbal medications at least 7 days prior to first dose of study 
treatment.
6.3.2.8 Medications that may prolong the QT interval or have a known risk of 
inducing Torsades de Pointes
LDK378 has potent activity  on the hERG channel with an IC50of 0.4 μM. There were no 
LDK378 -related effects in vivo in monkey s at doses as high as 100 mg/kg (human equivalent 
dose [HED] of 1950 mg).  Serial ECGs were collected following a single dose and at steady -
state to evaluate the effect of LDK378 on the QT interval in an open -label, dose-escalation, 
and expansion Study  [CLDK378X2101] . A total of 304 patients were treated with LDK378 
doses ranging from 50 to 750 mg with 255 patients treated with LDK378 750 mg. One of 304 
patients (<1%) was found to have a QTc >500 ms and 10 patients (3.3%) had an increase from 
baseline QTc >60 ms. A central tendency  analysis of the QTc data at average steady -state 
concentrations demonstrated that the upper bound of the 2-sided 90% CI for QTc was 16 ms 
at LDK378 750 mg. A pharmacokinetic/pharmacody namic analysis suggested concentration -
dependent QTc interval prolongation.
Concomitant use of LDK378 and any medi cation included in Appendix 1, Table 14-4 titled 
“List of prohibited QT prolonging drugs” (i.e., drugs that are generally accepted by the 
Qtdrugs.org Advisory  Board of the Arizona CERT 
to have a known risk of causing Torsades 
de Pointes) is not permitted.

Novartis Confidential Page 67
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.4 Patient numbering, treatment assignment o r randomization
6.4.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.) that is assigned 
when the patient is first identified for pre-screening and is retained as the primary  identifier 
for the patient throughout the entire participation in the trial. The Subject No. consists of the 
center number (Center No.) as assigned by Novartis to the investigative site with a sequential 
patient number suffixed to it, so that each subject is numbered uniquely  across the entire 
database. Upon signing the Informed Consent Form (ICF), the patient is assigned to the next 
sequential Subject No. available to the investigator through the Oracle Clinical RDC interface. 
Once assigned, the Subject No. must not be reused for an y other subject .
If the patient fails to start treatment for any reason, the reason will be entered into the 
Screening Disposition eCRF page.
At the screening visit, the investigator or designated staff will contact the Interactive 
Response Technology  (IRT) system and provide the requested identify ing information for the 
patient to register them into the IRT system. At the C1D1 visit, before the patient receives the 
first dose, the IRT system must again be contacted to enroll the patient in the study . If the 
patient is a screen failure, IRT should be notified within 2 working day s that the patient was a 
screen failure and was not enrolled.
6.4.2 Treatment assignment or randomization
Not applicable.
6.4.3 Treatment blinding
Not applicable.
6.5 Stud y drug preparation and dispensation
 
 
 
 
 

Novartis Confidential Page 68
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.5.1 Study drug packaging and labeling
 
 
 
 
 
6.5.2 Drug supply  and storage
 
 
 
 
6.5.3 Study drug compliance and accountability
6.5.3.1 Study drug compliance
 
 
 
6.5.3.2 Study drug accountability
 
 
 
 
 
 
 
6.5.3.3 Handling of other study  treatment
Not applicable.

Novartis Confidential Page 69
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
6.5.4 Disposal and destruction
 
 
7 Visit schedule and assessments
7.1 Stud y flow and vi sit schedule
Table 7-1lists all of the assessments and indicates with an “X” the visits when they are 
performed. Each treatment cycle 
is 28 days (the 28 days cycle length is fixed regardless of 
whether the dose of LDK378 is withheld). All visits are to be scheduled according to the 
appropriate number of calendar day s from Cy cle 1 Day  1 of study  drug administration. A visit 
window of +/- 1 day in Cycle 1 and +/- 3 days in Cycle 2 onwards is allowed. Imaging 
evaluations may  be performed +/- 7 day s of the due date of the assessment . Note: If treatment 
with LDK378 is withheld at any time during the study, all study visits, safety and 
efficacy assessments should continue according to the appropriate number of calendar 
days from Cycle 1 Day 1 as per the schedule of assessments.
All data obtained from these assessments must be supported in the patient’s source 
documentation. eCRF will not be used as a source document. The table indicates which 
assessments produce data to be entered into the database (D) or remain in the source 
documents only  (S).

Novartis Confidential Page 70
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203
Table 7-1 Visit evaluation schedule
CategoryProtocol 
sectionScreening PhaseTreatment Phase
Post treatment 
efficacy / follow up 
phaseSurvival 
follow -
up 
phaseCycle 1
(28 d)Subsequent 
cycles
(28 d)End of 
study  
treatment 
(EOT)
Visit nameMolecular 
pre-screenScreening 
Visit
(Day -28 
to Day  -1)Cycle 1 
Day 1Cycle 1 
Day 15Cycle 2 Day  
1; Cycle 3 
Day 1; etc.End of 
treatment 
visitTumor 
follow -upStudy  
phase 
completionSurvival 
follow -
up
Obtain pre -screening 
informed consentD X
Obtain Main Informed 
ConsentD 11.3. X
Confirmation of ALK status 
by central laboratoryD 7.1.1 . New 
biopsy 
preferred 
and/or 
archival 
tissue & 
pathology 
report
End of Phase Disposition 
PageD 7.1. X X X
Patient history
Demography D 7.1.2.3 . X
Inclusion/ exclusion criteria D 5.2.
5.3.X
Eligibility check S 7.1.2.1 . X
Relevant medical history/ 
current medical conditionsD 7.1.2.3 . X

Novartis Confidential Page 71
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203CategoryProtocol 
sectionScreening PhaseTreatment Phase
Post treatment 
efficacy / follow up 
phaseSurvival 
follow -
up 
phaseCycle 1
(28 d)Subsequent 
cycles
(28 d)End of 
study  
treatment 
(EOT)
Visit nameMolecular 
pre-screenScreening 
Visit
(Day -28 
to Day  -1)Cycle 1 
Day 1Cycle 1 
Day 15Cycle 2 Day  
1; Cycle 3 
Day 1; etc.End of 
treatment 
visitTumor 
follow -upStudy  
phase 
completionSurvival 
follow -
up
Diagnosis and extent of 
cancerD 7.1.2.3 . X
Prior antineoplastic 
therapies (meds, surgery, 
radiation)D 7.1.2.3 . X
Prior and concomitant 
medicationsD 6.3. Continuous
Physical examination S 7.2.2.1 . X X X X X
Performance status ( WHO) D 7.2.2.4 . X X X X
Height D 7.2.2.3 . X
Weight D 7.2.2.3 . X X X X
Vital signs D 7.2.2.2 . X X X X X
Laboratory  assessments
Hematology D 7.2.2.5.1 . X X X X X
Blood chemistry D 7.2.2.5.2 . X X X X X
Urinalysis (dipstick) with 
micro -analysisD 7.2.2.5.3 . X
Pregnancy test D 7.2.2.5.4 . X X X X
Testosterone, LH, FSH, 
sex hormone binding 
globulin (SHBG) (males 
only)D 7.2.2.5.5 . X X X
Coagulation D 7.2.2.5.6 . X

Novartis Confidential Page 72
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203CategoryProtocol 
sectionScreening PhaseTreatment Phase
Post treatment 
efficacy / follow up 
phaseSurvival 
follow -
up 
phaseCycle 1
(28 d)Subsequent 
cycles
(28 d)End of 
study  
treatment 
(EOT)
Visit nameMolecular 
pre-screenScreening 
Visit
(Day -28 
to Day  -1)Cycle 1 
Day 1Cycle 1 
Day 15Cycle 2 Day  
1; Cycle 3 
Day 1; etc.End of 
treatment 
visitTumor 
follow -upStudy  
phase 
completionSurvival 
follow -
up
Imaging
CT scan or MRI of chest 
and abdomenD 7.2.1 . X Cycle 3 then 
every 2nd
cycle (i.e. 
every  8 
weeks )X Every  8 
weeks
following 
EOT until 
PD
Whole body bone scan D 7.2.1 . X
CT scan or MRI of brain D 7.2.1 . X Cycle 3 then 
every 2nd
cycle (i.e. 
every 8 
weeks): only 
if clinically 
indicated or 
positive at 
baselineOnly if 
clinically 
indicated or 
positive at 
baselineEvery 8 
weeks 
following 
EOT until 
PD (only if 
clinically 
indicated 
or positive 
at 
baseline)

Novartis Confidential Page 73
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203CategoryProtocol 
sectionScreening PhaseTreatment Phase
Post treatment 
efficacy / follow up 
phaseSurvival 
follow -
up 
phaseCycle 1
(28 d)Subsequent 
cycles
(28 d)End of 
study  
treatment 
(EOT)
Visit nameMolecular 
pre-screenScreening 
Visit
(Day -28 
to Day  -1)Cycle 1 
Day 1Cycle 1 
Day 15Cycle 2 Day  
1; Cycle 3 
Day 1; etc.End of 
treatment 
visitTumor 
follow -upStudy  
phase 
completionSurvival 
follow -
up
CT scan or MRI of other 
metastatic sites (e.g. neck, 
pelvis, etc)
Localized bone CT scan, 
MRI or x -ray (for any 
lesions identified on the 
whole body bone scan that 
are not visible on the 
chest/abdomen CT scan or 
MRI)
Photography (for any skin 
lesions)D 7.2.1 . X (if 
clinically 
indicated)Cycle 3 then 
every 2nd
cycle (i.e. 
every 8 
weeks): only 
if positive at 
baseline or 
clinically 
indicatedOnly if 
positive at 
baseline or 
clinically 
indicatedEvery 8 
weeks 
following 
EOT until 
PD (only if 
positive at 
baseline 
or 
clinically 
indicated)
Study  drug administration
LDK378 dosing D 6.1. Continuous
Safety
Adverse events D 8.1. Continuous
ECG D 7.2.2.6.1 . X X X X X

Novartis Confidential Page 74
Amended Protocol Version 04 (Clean) Protocol No. CLDK378A2203CategoryProtocol 
sectionScreening PhaseTreatment Phase
Post treatment 
efficacy / follow up 
phaseSurvival 
follow -
up 
phaseCycle 1
(28 d)Subsequent 
cycles
(28 d)End of 
study  
treatment 
(EOT)
Visit nameMolecular 
pre-screenScreening 
Visit
(Day -28 
to Day  -1)Cycle 1 
Day 1Cycle 1 
Day 15Cycle 2 Day  
1; Cycle 3 
Day 1; etc.End of 
treatment 
visitTumor 
follow -upStudy  
phase 
completionSurvival 
follow -
up
Biomarker studies
Survival follow -up
Antineoplastic therapies 
since discontinuation of 
study treatmentD 7.1.4.1 . X X
Survival assessment 7.1.4.1 . X

Novartis Confidential Page 75
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
7.1.1 Pre-screening
Prescreening will involve all activities until the determination of ALK status by the central 
laboratory .
Patients will be consented for a pre-screening visit. If a patient is being treated with 
chemotherap y for their NSCL C, pre-screening may be performed during the chemotherap y 
treatment. However, if a patient is determined to be ALK positive, the patient must only be 
screened when progression of disease on chemotherap y treatment (if such treatment is being 
used) is confirmed.
Preferably , a newl y obtained tumor biopsy  should be submitted for all patients to determine 
ALK status and trial entry  eligibility . If the new biopsy  cannot be obtained, a formalin -fixed 
paraffin-embedded (FFPE) tumor sample(s) from archival material obtained at the time of 
diagnosis of NSCL C or any time since must be submitted for central analysis. Analy sis 
material must be sent immediately  upon the patient entering molecular pre-screening. If 
unstained slides cannot be prepared, paraffin blocks can be submitted. Sections will be cut 
from paraffin block and the remaining material will be returned to the site upon request. The 
translocation analysis to confirm ALK rearrangement will be the FDA -approved FISH test 
(Abbott Molecular Inc) using Vysis break- apart probes.
ALK status must be determined centrally  prior to screening assessments being performed. 
Instructions for tumor sampling, preparation and packing are described in a separate 
laboratory  manual. Molecular pre-screening samples must consist of tumor tissue (which may 
include fine-needle aspirates) but cannot consist of a cytology  sample obtained from fluid 
collections (e.g. pleural, pericardial or ascitic effusions), as the FDA -approved FISH test is 
not validated on such samples.
Results of the assay  will be sent to the site. If delay s are experienced in p rocessing the sample, 
the pre-screening site will be informed. Results of the ALK rearrangement status must be 
received before the patient is permitted to attend the screening visit.
7.1.2 Screening
Screening assessments to confirm eligibility  should be performe d as per the schedule of 
assessments. Written informed consent must be obtained before any study specific procedure 
is performed.
Re-screening of patients will not be allowed, but laboratory  parameters which do not meet the 
inclusion criteria may  be re -tested within the 28 day screening window.
7.1.2.1 Eligibility  screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility  check will be embedded in the IRT 
system. Please refer to and comply  with the detailed guidelines in the IRT manual.

Novartis Confidential Page 76
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
7.1.2.2 Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for any reason will 
be considered a screening failure.
The following eCRFs must be completed for screening failure patients:
Screening Phase Disposition page (including reason for not being started on treatment)
Informed consent
Demograph y
Adverse Events (onl y if an SAE occurs)
Inclusion/Exclusion criteria
7.1.2.3 Patient demo graphics and other baseline characteristics
Data to be collected on patient characteristics at screening include:
Demograph y (including: date of birth, age, patient initials, gender, childbearing potential, 
race and ethnicity, or as allowed by local regula tions)
Relevant medical history
NSCL C diagnosis and extent of disease, including:
Date of diagnosis and stage of NSCL C
ALK status documentation using the FDA -approved Vy sis ALK break- apart FISH 
assay . ALK status must be confirmed using the FDA- approved Vy sis ALK break-
apart FI SH test via a central laboratory using the new biopsy  obtained prior to study  
entry  (if biopsy  was taken) or, if a new biopsy  is not available, using the required 
archival tumor tissue.
Site of active disease
Characteristics of dise ase
Prior antineoplastic therapies (medications, radiation, surgeries)
Prior and Concomitant Medications, surgical and medical procedures
All other medications taken within 28 days before the first dose of study  treatment is 
administered must be recorded on the Prior and Concomitant medication eCRF page and 
updated on a continual basis if there is new change to the medication.
7.1.3 Treatment period
The study  treatment phase begins on Cycle 1, Day 1 with the first administration of LDK378 
and will continue until unacceptable toxicity  that precludes further treatment, start of a new 
anti-cancer therapy , treatment is discontinued at the discretion of the investigator and/or 
patient death. If a patient experiences disease progression (radiologically  documented 
accord ing to RECIST 1.1 as assessed by the investigator), LDK378 administration may be 
stopped, or may be continued if the patient is continuing to derive clinical benefit in the 
opinion of the investigator (see Section 6.1.3 ).
Patients will be assessed as per visit schedule in Table 7 -
1.

Novartis Confidential Page 77
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Visit windows of ±1 calendar day will be applicable to scheduled study  assessments during 
Cycle 1. Visit windows of ± 3 days from scheduled study  assessments will apply  during and 
beyond Cycle 2. The only exception is imaging assessments, which have a 7 day window at 
all scheduled timepoints.
7.1.4 Discontinuation of study treatment
7.1.4.1 Patients discontinuing LDK378 
A patient will be defined as on the study  if they are continuing to have any study  data 
collected, i.e. 
if the patient is being treated with LDK378, is in efficacy  follow -up after 
discontinuing LDK378, or is in survival follow-up.
Patients may voluntarily  discontinue from the study  treatment for any reason at any time. If a 
patient decides to discontinue from the study  treatment, the investigator must make every  
effort (e.g. telephone, e-mail, letter) to determine the primary  reason for this decision and 
record this inform ation in the patient’s chart and on the appropriate CRF pages. They  may be 
considered withdrawn if they  state an intention to withdraw, fail to return for visits, or become 
lost to follow -up for an y other reason. 
The investigator should discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would be detrimental to the patient’s well -being.
Study  treatment must be discontinued under the following circumstances:
Emergence of adverse events, as described in Section 6.3
Laboratory  abnormalities, as described in Section 6.3
Pregnancy
Deviations from the prescribed dose regimen, as described in Section 6.2.3
Use of prohibited treatment, as described in Appendix 1 for L DK378
Any other protocol deviation that results in a significant risk to th e patient’s safet y
Study  Terminated by  Sponsor
Patient/guardian decision
Physician decision
Lost to follow -up
Death
Patients who discontinue study  treatment should NOT be considered withdrawn from the 
study . They  should return for the assessments indicated in Section 7.2.1 and enter the survival 
follow -up period or continue tumor assessments as appropriate. If they fail to return for these 
assessments for unknown reasons, every  effort 
(e.g. telephone, email, letter) should be made 
to contact them as specified in Section 7.1.6.
End of treatment visit
Patients who discontinue LDK378 should be scheduled for a visit as soon as possible and 
within 7 days ofthe last dose of LDK378, at which time all of the assessments listed for the 
EOT visit will be performed. If a patient withdraws from treatment at a study  visit, EOT 

Novartis Confidential Page 78
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
assessments do not need to be repeated. An End of Treatment Phase Disposition eCRF page 
should be completed, giving the date and reason for stopping LDK378 treatment. As a 
minimum, all patients who discontinue LDK378, including those who refuse to return for a 
final visit, will be contacted for safet y evaluations at least 30 days after the last dose of 
LDK378. The investigator should inquire about any AE observed/concomitant medication 
taken during this 30-day period. This can be done via a phone contact. Antineoplastic 
therapies will be captured on the 'Antineoplastic therapies since discontin uation of study  
treatment' eCRF page following the last dose of the LDK378.
7.1.4.2 Withdrawal of consent
 
 
 
 
 
 
 
 
 
 
7.1.5 Follow -up period 
7.1.5.1 Post -treatment efficacy  follow -up
If a patient discontinues study  treatment in the absence of confirmed PD, tumor assessments 
every  8 weeks should continue to be performed from the EOT visit until PD is assessed by  the 
investigator (see Section 7.2.1.2); however, safety  assessments do not need to continue to be 
performed. .Antineoplastic therapies since discontinuation of study  treatment will continue to 
be collected.
Once the patient ceases tumor follow -up, the reason for completion should be recorded on the 
Study  Phase Completion Disposition eCRF page.
7.1.5.2 Survival follow -up
Following the end of tumor follow -up for efficacy  (i.e. after the time of confirmed PD), the 
patient will be contacted every  3  m onths to determine survival status and antineoplastic 
therapies since discontinuation of study  treatment.
7.1.6 Lost to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show "due diligence" by contacting 

Novartis Confidential Page 79
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
the patient, family  or family  physician as agreed in the informed consent and by documenting 
in the source documents steps taken to contact the patient, e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Tumor evaluation will be determined locally  according to the Novartis guideline ( Appendix II )
on the Response Evaluation Criteria in Solid Tumors (RECI ST), based on RECI ST Version 
1.1 ( Eisenhauer et al 2009 ). The investigator’s assessment will be used for the primary 
endpoint anal ysis and for p atient’s treatment decision making.
Imaging data will be centrally  collected and checked for qualit y by an imaging Clinical 
Research Organization (CRO) designated by Novartis. It will undergo review by a blinded 
independent review committee (BIRC) accordin g to the Novartis guideline (Appendix II) on 
the Response Evaluation Criteria in Solid Tumors (RECI ST), based on RECI ST Version 1.1.
Full details of the central reading process are included in the BIRC Charter.
7.2.1.1 Baseline assessments
Details of imaging requirements and logistics can be found in the separate Imaging Manual.
Tumor evaluation will be performed at baseline within 28 days of, and prior to, enrollment. 
Contrast -enhanced CT (or MRI ) should prefer ably be performed using a 5 mm slice thickness 
with a contiguous reconstruction algorithm. CT/MRI  scan slice thickness should not exceed 8 
mm cuts using a contiguous reconstruction algorithm.
Required conditions for tumor assessment at baseline
Patients mu st have measurable disease as per RECI ST 1.1 ( Appendix II ). Measurable 
lesions include ly tic or mixed (ly tic + blastic) bone lesions with an identifiable soft tissue 
component that meets the measurabili ty criteria per RECI ST 1.1 ( Appendix II ).
Patients with only  non
-measurable lesions are not eligible.
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confir med b y cytology /histology .
Any potentiall y measurable lesion that has been previously treated with radiotherap y 
should be considered as a non- measurable lesion. However, if a lesion previously  treated 
with radiotherap y has clearly progressed since the radi otherap y, it can be considered as a 
measurable lesion.
All measurable lesions up to a maximum of 5 nodal and/or non -nodal lesions in total (and 
a maximum of 2 lesions per organ), representative of all involved organs, should be 
identified as target lesions and recorded and measured at baseline.

Novartis Confidential Page 80
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Required image assessments for tumor assessment at baseline
The following assessments will be performed:
Computed Tomograph y (CT) with I V contrast or Magnetic Resonance Imaging (MRI) of 
chest and upper abdomen.
The preferred radiologic technique is CT with intravenous (IV) contrast. If a patient is 
known to have a contraindication to CT contrast media or develops a contraindication 
during the trial, a non -contrast CT of the chest (MRI  is not recommended due to 
respir atory  artifacts) plus a contrast- enhanced MRI (if possible) of the upper abdomen 
should be performed.
A whole bod y bone scan according to institutional guidelines (e.g. Tc -99 bone scan, whole 
body  bone MRI, FDG -PET or sodium fluoride positron emission tomo graphy  (NaF PET)) .
After screening, scans need not be repeated, unless clinically indicated. If indicated, 
the same methodology as at screening should be used.
Localized CT, MRI  or X -rays of all skeletal lesions identified on the screening bone scan, 
which are not visible on the chest and abdomen CT/MRI  (and pelvis CT/MRI  if 
applicable).
After screening, scans need not be repeated, unless clinically indicated. If indicated, 
the same methodology as at screening should be used.
Brain CT with IV contrast or MR I scan.
After screening, scans need not be repeated, unless clinically indicated. If indicated, 
the same methodology as at screening should be used.
Color photographs (with a metric ruler) if skin lesions are present.
After screening, scans need not be rep eated, unless clinically  indicated. If indicated, 
the same methodology as at screening should be used.
CT or MRI of any  other site of disease not captured by  any of the above listed images (e.g., 
pelvis, neck).
After screening, scans need not be repeated, unless clinically  indicated. If indicated, 
the same methodology as at screening should be used.
Any imaging assessments alread y completed during the regular work -up of the patient within 
6 weeks prior to start of treatment, including before signing the main study  ICF, can be 
considered as the baseline images for this study .
Chest x -ray or ultrasound must not be used to measure tumor lesions.
7.2.1.2 Subsequent image assessments for response determination
Tumor assessment for response determination will be made every 8 weeks starting from Day 
1 of cycle 1 (+/- 7 days window). The 8 weeks interval should be respected regardless of 
whether treatment with LDK378 is temporarily withheld.

Novartis Confidential Page 81
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Post -baseline tumor ass essments
The following assessments will be performed at on- study  scheduled visits (see Table 7 - 1):
Computed Tomograph y (CT) or Magnetic Resonance Imaging (MRI) of chest and upper 
abdomen.
Localized CT, MRI  or X -rays of all skeletal lesions identified on the screening bone scan, 
which are not visible on the chest and upper abdomen CT/MRI  (and pelvis CT/MRI  if 
applicable). Whole bod y bone scans need not be repeated after baseline unless clinically  
indicate d.
Brain CT with IV contrast or MRI , if brain metastases were identified at baseline.
Color photographs (with a metric ruler) if skin lesions were documented at baseline.
CT or MRI  of any  other site of disease documented at baseline (e.g., pelvis, neck).
For post-baseline tumor assessments, all lesions that were present at baseline must be 
accounted for using the same technique as used at baseline so that the comparison is 
consistent. If possible, a single radiologist should perform all tumor response evalu ations for 
an individual patient.
All study  imaging performed, including any intercurrent imaging studies, whether or not 
suspected to fulfill a progression or response criterion, should be submitted to the designated 
imaging CRO for quality  control and the BIRC review promptly  after acquisition. The 
activities of the imaging CRO and the BIRC will be described in the Imaging Charter.
Criteria required for determining partial or complete response should be confirmed by a 
subsequent imaging assessment at least 4 weeks later. If an off-schedule imaging assessment 
is performed to confirm response or if progression is suspected, subsequent imaging 
assessments should be performed in accordance with the original imaging schedule unless the 
next scheduled imaging timepoint is within 2 weeks, in which case the scheduled imaging 
timepoint can be omitted.
Combined PET/CT may be used only if the CT is of similar diagnostic quality  as a CT 
performed without PET, including the utilization of oral and IV contrast media. At the 
discretion of the Investigators, FDG -PET scans may be performed to document progressive 
disease per RECIST 1.1 ( Appendix II ).
Imaging evaluations will be performed at the End of Treatment (EOT) visit. If a patient is 
known to have PD at a scheduled study  visit, EOT imaging evaluations do not need to be 
repeated for the EOT visit.
Imaging assessment by  the BIRC
All radiological assessments will be read locally  and should be submitted promptly  after 
acquisition to the imaging CRO designated by  Novartis. The process at the imaging CRO will 
ensure that the BIRC remains blinded to the results of the local assessment (and other 
unblinding information). The decision regarding patient management will remain with the 
local investigator.

Novartis Confidential Page 82
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Rapid image transmission to the BIRC may be accomplished by uploading all digital images 
acquired b y the investigator in a secured website.
The results of the BIRC assessment will not be communicated to sites.
All timepoints will be read on an ongoing basis (rolling reads) as detailed in the imaging 
charter to be provided b y the designated imaging CRO.
Duration of post -baseline tumor assessments
Tumor assessments will continue until one of the following events:
The patient exp eriences RECI ST-defined PD as determined by  the investigator AND 
treatment with LDK378 ceases. If treatment with LDK378 continues beyond RECI ST-
defined PD, imaging assessments must continue every  8 weeks until L DK378 treatment 
ceases
If a patient discontin ues study  treatment in the absence of PD, tumor assessments will 
continue to be performed every  8 weeks until the patient experiences a RECI ST-defined 
PD as determined b y the investigator
Death
Lost to follow -up, or
Patient decision involving withdrawal of consent (see Section 7.1.4.1).
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by the assessments described below as well as the collection of AEs 
at every  visit. For details on AE collection and reporting, refer to Section 8. Significant 
findings that were present prior to the signing of informed consent must be included in the 
relevant medical history /current medical conditions page on the patient’s eCRF. Significant 
new findings that begin or worsen after informed consent must be recorded on the Adverse 
Event page of the patient’s eCRF.
7.2.2.1 Physical examination
Physical examinations will include an examination of general appearance, skin, neck 
(including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, and a basic nervous system evaluation. Information about the physical 
examination must be present in the source documentation at the study  center. For the 
assessment schedule refer to 
Table 7-1.
Significant findings that were present prior to the signing of informed consent must be 
included in the Medical History page on the patient’s eCRF. Significant new findings that 
begin or worsen after informed consent must be recorded on the Adverse Event page of the 
patient’s eCRF.
7.2.2.2 Vital signs
Vital signs include body  temperature, blood pressure and pulse measurements. Blood pressure 
(systolic and diastolic) and pulse should be measured after the patient has been sitting for five 
minutes.

Novartis Confidential Page 83
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
For the assessment schedule refer to Table 7 -1.
7.2.2.3 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured. Height will be measured at screening only. For 
the assessment schedule for weight refer to Table 7 -
1.
7.2.2.4 Performance status
WHO performance status will be assessed as per the assessment schedule (refer to Table 7-1 ).
Assessment of WHO performance status (Table 7-2) will be performed within the time 
windows described above of the scheduled assessment, even if study  medication is being held. 
More frequent examinations may be performed at the investigator’s discretion, if medically 
indic ated.
Table 7
-2 WHO performance status scale
Score Performance Status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g. light housework, office work
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
7.2.2.5 Laboratory  evaluations
Central laboratories will be used for the analysis of scheduled hematology, biochemistry  and 
other blood specimens collected as part as safet y monitoring. All unscheduled blood testing 
will be performed locally. Dipstick urinaly sis will be performed locall y, except in the case of 
any out of range parameter on scheduled local urine analy sis, when a urine sample will be 
sent to central laboratory  for further analysis. Details on the collection, shipment of blood, 
urine and tumor samples and reporting of resul ts by the central laboratory  are provided to 
investigators in a separate [Laboratory  Manual] . The time windows granted for laboratory 
evaluations are identical to the corresponding visit time windows for each visit (refer to 
Section 7.1).
Laboratory  values obtained at the screening visit will be used to assess eligibility  to meet 
inclusion criteria 7. In addition, eligible patients must have baseline laboratory  assessments 
performed on Cy cle 1 Day  1 / Ru n
-in Day  1 or within 24 hours prior to dosing. The results of 
centrall y-analyzed laboratory  assessments performed at Cycle 1 Day 1 do not need to be 
received b y the site prior to initiation of dosing.

Novartis Confidential Page 84
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Table 7-3 Clinical laboratory  parameters collection plan
Test Category Test Name
Hematology Hemoglobin, platelets, white blood cells (W BC), red blood cells (RBC), differential 
(basophils, eosinophils, lymphocytes, monocytes, neutrophils [% or absolute])
Blood Chemistry Albumin, ALT, AST, calcium (at screening calcium corrected for albumin), creatinine, 
creatinine clearance, total bilirubin, direct bilirubin (only if total bilirubin is ≥ grade 2), 
blood urea nitrogen (BUN) or urea, magnesium, potassium, sodium, fasting glucose, 
phosphate (inorganic phosphorus), alkaline phosphatase, amylase, GGT , lipase
Urinalysis Macroscopic panel (dipstick) (bilirubin, blood, glucose, ketones, W BC, pH, protein, 
specific gravity)
Microscopic panel (RBC, W BC, casts)
Hormones (males only) Testosterone, LH, FSH, sex hormone binding globulin (SHBG)
Coagulation INR and pro -thrombin time (PT) or Quick Test
Details on the collections, shipment of samples and reporting of results by the central 
laboratory  are provided to investigators in the [Laboratory  Manual] .
7.2.2.5.1 Hematology
Hematology  assessments of the parameters listed in Table 7-3will be tested as per the 
schedule of assessments ( Table 7
-1).
7.2.2.5.2 Blood chemistry
Blood chemistry  assessments of the parameters listed in Table 7-3will be tested as per the 
schedule of assessments ( Table 7
-1).
7.2.2.5.3 Urinalysis
Dipstick measurements will be performed as per Table 7-3and according to the schedule of 
assessments. Any significant findings on dipstick will be followed up with microscopic 
evaluation as per Table 7 -
3.
7.2.2.5.4 Pregnancy and assessments of fertility
All women of childbearing potential must complete a serum pregnancy  test at the screening 
visit, at Cycle 1 Day 1, at every  cycle throughout the study  and at End of Treatment. Central 
laboratories will be used for the analy sis of serum pregnancy  tests.
Women who are determined not to be of child bearing potential before the study  will only be 
tested at screening. When non-child bearing potential status is determined during the study , 
further pregnancy  testing will not be continued. Women are considered post-menopausal if 
they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history  of vasomotor symptoms), and otherwise not of child 
bearing potential if they have had surgical bilateral oophorectomy (with or without 
hysterectom y) or tubal ligation at least six weeks ago. In thecase of bilateral oophorectom y 
alone, only when the reproductive status of the woman has been confirmed by follow up 
hormone 
level assessment is she considered not of child bearing potential (such testing is not 
covered as part of the study  assessments).

Novartis Confidential Page 85
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
The time windows granted for pregnancy  testing are identical to the corresponding visit time 
windows for each visit. Refer to Table 7 -1.
7.2.2.5.5 Hormones
Testosterone, LH, FSH and sex hormone binding globulin (SHBG) will be tested in male 
patients only  and as per the schedule of assessments ( Table 7 -1).
7.2.2.5.6 Coagulation
INR and pro-thrombin time (PT) or Quick Test will be measured at screening onl y.
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed
At the screening visit, in triplicate.
At Cy cle 1 Day  1, in triplicate, pre -dose, and in triplicate 6 hours (+/ - 30 minutes) after 
dosing. 
At Cy cle 1 Day  15 and at Cy cle 2 Day  1 in tr iplicate, pre -dose.
 
 
At other defined timepoints (Day  1 of subsequent cy cles) (see 
Table 7 -1) as single ECGs, 
pre-dose.
ECGs will be performed in supine position. All ECGs recorded for each time point will be 
transmitted electronically to a central laboratory  and will be centrally  reviewed by an 
independent reviewer. Any original ECG not transmitted electronically  to the 
central 
laboratory  should be forwarded for central review.
Interpretation of the tracing must be made by a qualified physician. Each ECG tracing should 
be labeled with the study  number, patient initials (where regulations permit), patient number, 
date, and kept in the source documents at the study  site. Clinically  significant abnor malities 
present when the patient signed informed consent should be reported on the Medical History  
eCRF page. Clinicall y significant findings must be discussed with Novartis prior to enrolling 
the patient in the study. New or worsened clinically  significa nt findings occurring after 
informed consent must be recorded on the Adverse Events eCRF page. When triplicate ECGs 
are taken, for the purposes of inclusion criteria and dose level management, mean parameter 
values should be used.

Novartis Confidential Page 86
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 87
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 88
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 89
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
 
 
7.2.5 Resource utilization
Not applicable.

Novartis Confidential Page 90
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
8 Safety  monitoring and reporting
8.1 Adverse events (A Es)
8.1.1 Definitions and reporting
An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), 
symptom(s), or medical condition(s) that occur after patient’s signed informed consent has 
been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute AEs 
only if they induce clinical signs or symptoms, are considered clinicall y significant, require 
therap y (e.g., hematologic abnormality  that requires transfusion or hematological stem cell 
support), or require changes in stud y medication(s).
AEs that begin or worsen after informed consent has been obtained should be recorded in the 
Adverse Events eCRF. Conditions that were alread y present at the time of informed consent 
should be recorded in the Medical History  page of the patient’s eCRF. AE monitoring should 
be continued for at least 30 days following the last dose of study  treatment. AEs (including 
lab abnormalities that constitute AEs) should be described using a diagnosis wheneve r 
possible, rather than individual underly ing signs and symptoms. When a clear diagnosis 
cannot be identified, each sign or s ymptom should be reported as a separate AE.
AEs will be assessed according to the Common Terminology  Criteria for Adverse Events 
(CTCAE) version 4.03 (dated 14 June 2010). If CTCAE grading does not exist for an AE, the 
severit y of mild, moderate, severe, and life -threatening, corresponding toGrades 1 -4, will be 
used. CTCAE Grade 5 (death) will not be used in this study ; rather, information about deaths 
will be collected though a Death eCRF. The occurrence of AEs should be sought by non-
directive questioning of the patient during the screening process after signing informed 
consent and at each visit during the study . AEs also may be detected when they are 
volunteered by the patient during the screening process or between visits, or through physical 
examination, laboratory  test, or other assessments. As far as possible, each AE should be 
evaluated to determine:
1.The severit y grade (CTCA E Grade 1-4)
2.Its duration (Start and end dates)

Novartis Confidential Page 91
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, perm anentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7.Whether it is serious, where a serious AE (SAE) is defined as in Section 8.2.1 .
All AEs should be treated appropriatel y. If a concomitant medication or non-drug therap y is 
given, this action should be recorded on the Adverse Event eCRF.
Once an AE is detected, it should be followed until its resolution or until it is judged to be 
permanent, and assessment should be made at each visit (or more frequently , if necessa ry) of 
any changes in severit y, the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by use 
of appropriate 
method (for example, as per RECI ST criteria for solid tumors), should not be reported as a 
SAE.
AEs separate from the progression of malignancy  (example, deep vein thrombosis at the time 
of progression or hemopty sis concurrent with finding of disease progression) will be reported
as per usual guidelines used for such events with proper attribution regarding relatedness to 
the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an AE in their own right (are considered clinicall y 
significant, induce clinical signs or sy mptoms, require concomitant therapy  or require changes 
in study  treatment), should be recorded on the Adverse Events eCRF. Whenever possible, a 
diagnosis, rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). 
Laboratory  abnormalities that meet the criteria for AEs should be followed until they have 
returned to normal or an adequate explanation of the abnormalit y is found. When an abnormal 
laboratory  or test result corresponds to a sign/sympto m of an alread y reported adverse event, 
it is not necessary  to separatel y record the lab/test result as an additional event.
Laboratory  abnormalities that do not meet the definition of an AE should not be reported as 
AEs. A Grade 3 or 4 event (severe) as per CTCAE does not automatically  indicate an SAE 
unless it meets 
the definition of seriousness below and/or at the investigator’s discretion. A 
dose hold or medication for the laboratory  abnormality  may be required by the protocol in 
which case the laborato ry abnormality  would, by  definition, be an AE and must be reported as 
such (see Section 6.2 ).

Novartis Confidential Page 92
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
8.1.3 Adverse events of special interest
Adverse events of special interest to be monitored for LDK378 have also been identified and 
include: hepatotoxicity , interstitial lung disease/pneumonitis, QT interval prolongation, 
bradycardia, hypergl ycemia gastrointestinal toxicity  (nausea, vomiting and diarrhea) and 
pancreatitis (including lipase and am ylase elevations).
Details regarding these adverse events are provided in the Investigator’s Brochure for 
LDK378 .Potential emergent new AEs will be monitored during the course of the study .
8.2 Serious adverse events
8.2.1 Definitions
An SAE is defined an AE characterized b y one of t he following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongation of existing hospitalization,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the info rmed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
Protocol exempt SAEs: Progression of malignancy (including fatal outcomes), if 
documented b y use of appropriate method (RECIST criteria), should not be reported as a 
serious adverse event.
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hou rs of learning of its occurrence.
Any SAE experienced after this 30 days period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study  treatment. Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow -up to the original 
episode within 24 hours of the investigator receiving the follow -up information. An SAE 

Novartis Confidential Page 93
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously reported one shoul d be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the investigator folder provided to each site Follow -up information is submitted in the 
same way as the original SAE Report Each re-occurrence, complication, or progression of the 
original event should be reported as a follow -up to that event regardless of when it occurs. 
The follow -up information should describe whether the event has resolved or continues, if and 
how it was treated, whether the blind was broken or not, and whether the patient continued or 
withdrew from stud y participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the Novartis study  treatment, an oncology 
Novartis DS&E department associate may urgently  require further information from the 
investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notification (IN), to inform all investigators involved in any study with the same drug that 
this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will 
be collected and reported to the competent authorities and relevant ethics committees (EC) in 
accordance with Directive 2001/20/EC or as per national regulatory  requirements in 
participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable. This is an open-label stud y.
8.4 Pregnancies
Patients who become pregnant during the trial will be withdrawn from the study . 
To ensure patient safet y, each pregn ancy  occurring while the patient is on study  treatment 
must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy 
should be followed until 3 months following delivery  to determine outcome, including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any 
birth defects, congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis DS&E. Pregnancy  follow -up should be recorded on the 
same form and should include an assessment of the possible relationship to the investigational 
treatment of any pregnancy  outcome. Any SAE experienced during pregnancy  must be 
reported on the SAE Report Form.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 

Novartis Confidential Page 94
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Brochure. Addition al safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.6 Data M onitoring Committee (DMC)
An independent Data Monitoring Committee (DMC) will be constituted and will be 
responsible for monitoring and reviewing the clinical study  data for efficacy  and safety  during 
the study  prior to the final data analysis. Efficacy  data will be reviewed periodicall y during 
Stage 1 to advise on whether the trial should proceed to Stage 2 and full enrolment. DMC 
review for the purpose of advising on the transition of the trial from Stage 1 to Stage 2 will be 
based primaril y on local inve stigator assessment of response. However, the DMC may  request 
data on assessment of response by the BIRC if deemed necessary . Responsibilities of the 
DMC, communication flow between DMC, Steering Committee and Novartis, and timing of 
data safety  and effica cy reviews, will be included in the DMC charter document.
It is envisioned that the DMC may make four t ypes of recommendations, namely :
1.Transition into Stage 2 of the trial or stopping enrollment after stage 1 for futility
2.No safet y or ethical issues, ethical to continue the trial as planned
3.Serious safet y concerns precluding further study treatment, regardless of efficacy
4.Ethical to continue the study  but recommend an amendment to the protocol (e.g. 
incorporate a safet y analysis).
8.7 Steering Committee (SC)
ASteering Committee (SC), comprised of investigators in NSCL C management from the 
study , will be formed prior to initiation of the trial. The purpose of the SC is to provide overall 
guidance regarding design of the study , conduct and execution of the trial to include (but not 
limited to) safety , accrual and contribution to scientific input for publications.
Responsibilities of the SCand communication flow between DMC, SC and Novartis will be 
included in the SCcharter document.
9 Data collection and manageme nt

Novartis Confidential Page 95
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator ’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, adherence to the 
protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed copy  is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the eCRF entries. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria 
and documentation of SAEs. Additional checks of the consistency  of the source data with the 
eCRFs are performed according to the stud y-specific monitoring plan.

Novartis Confidential Page 96
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 97
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
10 Statistical methods and data analy sis
The data from all participating centers in this protocol will be combined. The primary  anal ysis 
of study  data will be conducted at the time when all patients have either completed at least six 
cycles of treatment or discontinued treatment. These data will be summarized in the primary 
Clinical Study  Report (CSR). The final analy sis of study  data will be conducted at the end of 
the study  
(see Section 4.3). All available data from all patients up to this cutoff date will be 
analyzed. Additional data from patients continuing to receive study  treatment after this time 
will be captured by a separate protocol. Efficacy and safet y reports will be reviewed by a 
DMC regularl y during the conduct of the stud y (see Section 8.6 for details).
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Analy sis Set (FAS) will include all patients who receive at least one dose of 
LDK378. Patients who are screened but never started treatment will be list ed.
The FAS will be used for all listings of raw data. Unless otherwise specified the FAS will be 
the default analy sis set used for all anal yses, including the primary  anal ysis.
10.1.2 Safety Set
The Safet y Set will include all patients who receive at least one d ose of LDK378.
10.1.3 Per-Protocol Set
The Per-Protocol Set (PPS) will consist of a subset of patients in the FAS who are compliant 
with requirements of the Clinical Study  Protocol (CSP). The PPS will include patients who 
have an adequate tumor assessment at baseline, a follow -up tumor assessment >7 weeks after 
starting treatment (unless disease progression is observed before that time), and no major 
protocol deviations.
All major protocol deviations leading to exclusion from the PPS will be detailed in the 
Report ing and Anal ysis Plan (RAP).

Novartis Confidential Page 98
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be summarized 
descriptivel y for all patients for the FAS. Categorical data will be presented as frequencies 
and percentages. For continuous data, mean, standard deviation, median, 25thand 75th
percentiles, minimum, and maximum will be presented.
10.3 Treatments (study  treatment, concomitant therapies, compliance)
The actual dose and duration in days of LDK378 as well as the dose intensity  (computed as 
the ratio of total dose received and actual duration) and the relative dose intensity  (computed 
as the ratio of dose intensity and planned dose intensity ),will be listed and summarized for all 
patients.
Dose reductions and dose interruptions (including the reasons for these) will be listed and 
summarized.
The safet y set will be used.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be summarized for all patients.
10.4 Primary  objective
The primary  objective is to evaluate the anti -tumor activity  of LDK378.
10.4.1 Variable
The variable used to evaluate the 
anti-tumor activity  of LDK378 is the overall response rate 
(ORR), defined as the proportion of patients with a best overall confirmed response of CR or 
PR, as assessed per RECIST 1.1 b y the investigator ( Appendix II ).
10.4.2 Statistical hy pothesis, model , and method of analy sis
The primary  anal ysis will be performed on the FAS.
The study
 targets an ORR of 50%. A response rate of 35% or less is considered as insufficient 
level of activity  for the proposed patient population. Therefore, a null hypothesis ofORR ≤ 
35% vs. an alternative hypothesis of ORR>35% will be tested using a one-sided test with 
alpha of 0.05 based on a Simon’s optimal two-stage design (Simon 1989). If 45 or more 
responses are seen in105 total patients (estimated ORR of 42.9%), then the null hypothesis 
will be rejected and the trial declared positive.
Stage 1 will enroll 43 patients. If the study  is terminated early at the end of Stage 1 (16 or 
fewer responses among 43 
patients enroll ed to Stage 1), then the study  will be considered to 
have failed to reject the null hypothesis . See Section 10.7 for further details of the stopping 

Novartis Confidential Page 99
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
criteria for futility . Stage 2 will include an additiona l 62 patients. The primary  analysis will 
occur when all 105 patients have completed 6 cycles of treatment or discontinued treatment 
earlier.
The ORR will be estimated and the 90% exact confidence interval (CI) will be provided. The 
uniformly  minimum varian ce unbiased estimator (UMVUE) and the 90% two-stage CI 
(Atkinson and Brown 1985 ) will also be presented.
10.4.3 Handling of missing values/censoring/discontinuations
Confirmed partial or complete responses reported prior to any additional anticancer therapy 
will be considered as responses in the calculation of the ORR irrespective of the number of 
missed assessments before response.
Patients with a best overall response of ‘Unknown’ or ‘Not Assessed’ per RECI ST1.1 will be 
considered as non -responders in estimating the ORR.
Patients who have disease progression and continue to receive treatment after progression will 
qualify  for progressive disease at the time of progression and will be counted as PD in ORR 
and other efficacy  calculations.
10.4.4 Supportive analy ses
The primary  anal ysis on the FAS will be repeated on the PPS.
ORR, per RECI ST 1.1, as assessed by the BIRC, will also be estimated and CIs will be 
provided based on the FAS as described in 
Section 10.4.2 .
10.5 Secondary  objectives
All secondary  efficacy  assessments (DOR, TTR, DCR, PFS, and OIRR) will be analyzed as 
per investigator assessment and as per the BIRC. Confirmation of response is required for all 
response endpoints, as per RECI ST 1.1.
All secondary  anal yses will be performed based on the FAS, unless otherwise specified.
No adjustment for multiple testing will be made.
10.5.1 Key secondary  objective(s)
Duration of response
Among patients with a confirmed respo nse (PR or CR) per RECI ST 1.1, duration of response 
(DOR) is defined as the time from first documented response (PR or CR) to the date of first 
documented disease progression or death due to any cause. DOR will be listed by patient and 
may be described using Kaplan -Meier curves and relevant statistics if appropriate. Censoring 
rules for DOR are described in the Appendix II.
Time to response
Time to response (TTR) is defined as the time from the date of the first dose of LDK378 to 
first documented response (CR or PR, which must be confirmed subsequently ) per RECI ST 

Novartis Confidential Page 100
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
1.1. TTR will be described using Kaplan -Meier methods and appropriate summary  statistics. 
The TTR anal ysis will be conducted with censoring rules as described in the Appendix II .
Disease control rate
The disease control rate (DCR), defined as the proportion of patients with best overall 
response of CR, PR, or SD per RECI ST 1.1 will be estimated and the 90% CI provided. DCR 
will be estimated.
10.5.2 Othe r secondary  efficacy  objectives
Progression- free survival
Progression- free survival (PFS) is defined as the time from the date of first dose of LDK378 
to the date of first documented disease progression per RECI ST 1.1 or death due to any  cause.
A patient who has not progressed or died at the date of the analysis or when he/she receives 
any further anticancer therapy  in the absence of disease progression will be censored at the 
time of the last adequate tumor evaluation before the earlier of the cut-off date or the 
anticancer therap y date. By default, if disease progression or death is documented after one 
single missing tumor evaluation, the actual event date of disease progression/death will be 
used for the PFS event date. If disease progression or death is documented after two or more 
missing tumor evaluations, the PFS time of these patients will be censored at the date of the 
last adequate tumor evaluation without PD.
PFS assessed by the investigators and the BIRC will be described using Kaplan -Meier 
methods and appropriate summary statistics.
Overall survival
Overall survival (OS) is defined as the time from the date of first dose of LDK378 to the date 
of death due to any  cause. OS time for patients who are alive at the end of the study  or are lost 
to fol low-up will be censored at the date of last contact.
OS will be described using Kaplan -Meier methods and appropriate summary  statistics.
Overall intracranial response rate (OIRR)
OIRR is calculated based on response assessments in the brain for patients having measurable 
brain metastases at baseline (i.e. at least one target lesion in the brain). OI RR is defined as the 
ORR based on target and non-target lesions in the brain and defined as the proportion of 
patients with a best overall confirmed response of CR or PR in the brain, as assessed per 
RECI ST 1.1 by  the investigator and b y BIRC.
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For all safet y analyses, the Safety  Set will be used. All listings and tables will be presented for 
all patients
.
The overall observation period will be divided into three mutually  exclusive segments:

Novartis Confidential Page 101
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
1.Pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2.On-treatment period: from day  of first dose of study  medi cation to 30 day s after last dose 
of study  medication
3.Post-treatment period: starting at day  31 after last dose of study  medication.
10.5.3.2 Adverse events (A Es)
Summary  tables for AEs will include only AEs that started or worsened during the on-
treatment period
. However, all safety  data (including those from the pre-and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged.
The incidence of AEs will be summarized by system organ class and/or preferred term, 
maximum severity  (based on Common Terminology Criteria for Adverse Events [CTCAE] 
grades version 4.03), and relation to study  drug.
Clinically  notable adverse events (CNAEs) will be considered. Such categories consist of one 
or more well- defined safety  events which are similar in nature and for which there is a 
specific clinical interest in connection with the study  treatment.
CNAEs will be defined at the project level and may be regularl y updated based on emergent 
data. For each specified CNAE, number and percentage of patients with at least one event in 
each CNAE category  will be reported.
10.5.3.3 Laboratory  abnormalities
For laboratory  tests covered by the CTCAE version 4.03, the study’s biostatistical and 
reporting team will grade laboratory  data accordingl y. For laboratory  tests covered by 
CTCAE, aGrade 0 will be assigned for all non-missing values not graded as 1 or higher. 
Grade 5 will not be used.
For some cases (e.g. white blood cell differentials), the lower limits of normal ranges used in 
CTCAE definitions will have to be replaced by a clinical meaningful limit expressed in 
absolute counts.
For laboratory  tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory
 normal ranges.
A listing of laboratory  values will be provided by laboratory  test, patient, and study  day. A 
separate listing will display  notable laboratory  abnormalities (i.e., newly occurring CTCAE 
grade 3 or 4 laboratory  abnormalities).
The following summaries will be generated separatel y for hematology and biochemistry 
laboratory  tests:
shift tables using CTCAE grades to compare baseline to the worst on -treatment value
for laboratory  tests where CTCAE grades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.

Novartis Confidential Page 102
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Listing of all laboratory  data with values flagged to show the corresponding CTCAE grades 
and the classifications relative to the laboratory  normal ranges will b e generated.
 
 
 
10.5.3.4 Other safety  data
Other safet y data collected will be listed and summarized using descriptive statistics as 
appropriate. Notable values may be flagged. Notable/Abnormal values for safety  data will be 
further specified in the RAP and will be used for shift tables.
Analy ses will be performed on the safety  set.
ECG
shift table for baseline to worst on -treatment result based on notable parameter categories
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
shift table baseline to worst on-treatment result
table with descriptive statistics at baseline and change from baseline to worst post -baseline 
time points.
10.5.3.5 Tolerability
Tolerability  will be summarized in terms of dose reductions or drug interruption due to an AE.

Novartis Confidential Page 103
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 104
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
10.7 Interim analy sis
In order to inform the recommendation to proceed to Stage 2 of the study , the DMC will 
periodicall y review response data during Stage 1, based on local investigator assessment, as 
defined in the DMC charter (see Section 8.6). The DMC may request data of assessment of 
response by the BIRC if deemed necessary  to provide its recommendation. As per Simon’s 
optimal two-stage design, the trial will be stopped at Stage 1 for futility  if 16 or fewer 
responses ar
e observed in the 43 patients enrolled to Stage 1. According to this rule, the DMC 
will make the recommendation to transition into the Stage 2 of the study . If at the time that the 
last patient is enrolled to Stage 1 a minimum of 17 responses have not yet been observed, 
accrual may be temporarily  suspended until either the minimum number of 17 responses are 
observed or all 43 patients have been followed for at least 6 cycles of LDK378 or 
discontinued treatment.

Novartis Confidential Page 105
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Safety  will be reviewed by a DMC regularl y during the conduct of the study , as outlined in 
the DMC charter document (see Section 8.6).
10.8 Sample size calculation
Based on Simon’s (1989) optimal two-stage design, if the true ORR is 50% (under the 
alternative hypothesis), approximately  105 total patients are required to reject the null 
hypothesis of ORR ≤ 35% with a one-sided alpha of 0.05 and 90% power. If at least 17 
confirmed responses are observed among 43 patients enrolled into Stage 1, an additional 62 
patients will be enrolled into Stage 2. If 45 or more confirmed responses are observed among 
105 total patients, the trial will be declared positive.
The operating characteristics of th e design are described in Table 10 -
1.
Table 10
-1 Operating characteristics of Simon’s optimal two -stage design
True ORR
35%
(null hy pothesis)40% 45% 50% (alternative 
hypothesis)
Probability stop for futility at Stage 1 
(16 or fewer responses out of 43 
patients enrolled at Stage 1)0.683 0.418 0.192 0.063
Probability trial is success (45 or more 
responses out of 105 total patients)0.049 0.268 0.642 0.900
10.9 Power for analy sis of key secondary  variables
Not applicable.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid d own in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Res earch 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature page confirming his/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access 
to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.

Novartis Confidential Page 106
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in 
Section 4.2.
11.5 Publication of stu dy protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.

Novartis Confidential Page 107
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 108
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
study  to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the cond uct of the study  this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safet y may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. UK requires the notification of 
urgent safet y measures withi n 3 day s) but not later than 10 working day s.

Novartis Confidential Page 109
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
13 References (available upon request)
Aaronson NK, Ahmedzai S, Bergman B, et al (1993) The European Organization for 
Research and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology . J Natl Cancer Inst; 85(5):365 -76.
Atkinson EN, Brown BW. Confidence limits for probability  of response in multistage phase II 
clinical trials. Biometrics; 41(3):741-4.
Benson AB 3rd, Ajani JA, Catalano RB, et al (2004) Recommended guidelines for the 
treatment of cancer treatment -induced diarrhea. J Clin Oncol ;22(14):2918-26.
Bergman B, Aaronson NK, Ahmedzai S, et al (1994) The EORTC QLQ -LC13: a modular 
supplement to the EORTC Core Quality  of Life Questionnaire (QLQ -C30) for use in lung 
cancer clinical trials. EORTC Study  Group on Quality  of Life. Eur J Cancer; 30A(5):635 -
42.
Crinò, Kim, Riely , et al (2011) Initial phase II results with crizotinib in advanced ALK -
positive non- small cell lung cancer (NSCLC): PROFILE 1005 [ abstract]. J Clin Oncol 29: 
2011 (suppl; 7514A).
Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid 
tumours: revised RECI ST guideline (version 1.1). Eur J Cancer; 45(2):228-47.
Fayers PM (2001) Interpreting qualit y of life data: population -based reference data for the 
EORTC QL Q-C30. Eur J Cancer; 37(11):1331 -4. Ferlay  J, Shin HR, Bray  F, et al (2010) 
Estimates of worldwide burden of cancer in 2008: GL OBOCAN 2008. Int J Cancer; 
127: 2893–2917.
Gettinger S, Ly nch T ( 2011) A decade of advances in treatment for advanced non -
small cell 
lung cancer. Clin Chest Med; 32(4):839-51.
Hollen PJ, Gralla RJ, Kris MG, et al (1993) Quality  of life assessment in individuals with lung 
cancer: testing the Lung Cancer S ymptom Scale (LC SS). Eur J Cancer; 29A Suppl 1:S51 -8.
Hollen PJ, Gralla RJ, Kris MG, et al (1994) Measurement of qualit y of life in patients with 
lung cancer in multicenter trials of new therapies. Psy chometric assessment of the Lung 
Cancer S ymptom Scale. Cancer; 73(8):20 87-98.
Hollen PJ, Gralla RJ, Kris MG, et al (2005) A comparison of visual analogue and numerical 
rating scale formats for the L ung Cancer Sy mptom Scale (L CSS): does format affect patient 
ratings of sy mptoms and quality  of life? Qual L ife Res; 14(3):837 -
47.
Kiura K, Seto T, Yamamoto N, et al (2012) A first -in-human phase I/II study of ALK 
inhibitors CH5424802 in patients with AL K-positive NSCL C [abstract]. J Clin Oncol 30, 
(suppl; 7602A).
Kwak EL, Bang YJ, Camidge DR (2010) Anaplastic ly mphoma kinase inhibit ion in non-
small -cell lung cancer. N Engl J Med; 363(18):1693 -703.  Malvezzi M , Bertuccio P, Levi F, 
et al (2012) European cancer mortalit y predictions for the year 2012. Ann Oncol; 23(4):1044-
52.
Mehra R, Camidge DR, Sharma S, et al (2012) First- in-human phase I study of the ALK 
inhibitor L DK378 in advanced solid tumors [abstract]. J Clin Oncol 30, 2012 (suppl; 3007A).

Novartis Confidential Page 110
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
National Cancer Institute: PDQ® Non -Small Cell Lung Cancer Treatment. Bethesda, MD: 
National Cancer Institute. Date last modified < 02/10 /2012>. Available 
at: .cancer.gov/cancertopics/pdq/treatment/non- small -cell-lung/healthprofessional. Accessed 
<07/29/2012>.
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology  
Non-Small Cell L ung Cancer (Version 3 .2012). Avai lable at .nccn.org Accessed 
<07/29/2012>.
Nguyen KS, Sanford RA, Huberman MS, et al (2012) Patterns of care for non -small -cell lung 
cancer at an academic institution affiliated with a national cancer institute -designated cancer 
center. J Oncol Prac; 8(1):5 7-62.
Ou SH (2011) Crizotinib: a novel and first
-in-class multitargeted t yrosine kinase inhibitor for 
the treatment of anaplastic ly mphoma kinase rearranged non-small cell lung cancer and 
beyond. Drug Des Devel Ther; 5:471
-485.
Scagliotti G, Stahel RA, Ros ell R, et al (2012) ALK translocation and crizotinib in non -small 
cell lung cancer: An evolving paradigm in oncology  drug development. Eur J Cancer; 
48(7):961-73.
Shaw AT, Yeap BY, Mino- Kenudson M, et al (2009) Clinical features and outcome of 
patients with non- small -cell lung cancer who harbor EML 4 -ALK. J Clin Oncol; 27:4247-
4253.
Shaw AT, Yeap BY, Solomon BJ, et al (2011) Effect of crizotinib on overall survival in 
patients with advanced non -small -cell lung cancer harbouring ALK gene rearrangement: a 
retrospective anal ysis. Lancet Oncol; 12(11):1004 -12.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, 
Blackhall F, Wu YL, Thomas M, O'By rne KJ, Moro -Sibilot D, Camidge DR, Mok T, Hirsh V, 
Riely  GJ, Iy er S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherap y in 
advanced ALK -positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385 -94. doi: 
10.1056/NEJMoa1214886. Epub 2013 Jun 1.
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin; 62(1):10 -
29.
Simon R (1989) Optimal two -stage designs for phase II clinical trials. Control Clin Trials; 
10(1):1-10.
Soda M, Choi YL , Enomoto M (2007) Identification of the transforming EML 4-ALK fusion 
gene in non -small -
cell lung cancer. Nature; 448(7153):561-6.
Takeuchi K, Choi YL, Togashi Y, et al (2009) KIF5B -
ALK, a novel fusion oncokinase 
identified by  an immunohistochemistry -based diagnostic s ystem for ALK -positive lung 
cancer. Clin Cancer Res; 15(9):3143 -9.
Weickhardt AJ, Rothman MS, Salian -Mehta S, et al (2012): Rapid -onset hy pogonadism 
secondary  to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer [Apr 4 
Epub ahead of print].

Novartis Confidential Page 111
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
14 Appendices
Appendix I: List of prohibited concomitant medications and concomitant 
medications requiring caution for LDK378
Appendix II: Harmonization of efficacy  analy sis of solid tumor studies 
(RECIST 1.1)

Novartis Confidential Page 112
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 113
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 114
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 115
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 116
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
MRI Magnetic resonance imaging
LPLV Last patient last visit
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

Novartis Confidential Page 117
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 118
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 119
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 120
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 121
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 122
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 123
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 124
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 125
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 126
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 127
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 128
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 129
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 130
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 131
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 132
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 133
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 134
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 135
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 136
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 137
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 138
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 139
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 140
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203

Novartis Confidential Page 141
Amended Protocol Version 04 (Clean) Protocol No. C LDK378A2203
5 References (available upon request)
Dent S, Zee (2001) application of a new multinomial phase II stopping rule using response 
and earl y progression, J Clin Oncol; 19: 785
-791.
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECI ST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47.
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465.
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005.
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May  2007.
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18.
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16.
